Document:

Form of Warrant dated October 26, 2005

 EXHIBIT 4.2 
  

EXECUTION VERSION 
  
 WARRANT 
  
 THE WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT (COLLECTIVELY, THE “SECURITIES”) REPRESENTED BY THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR
APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE
SECURITIES LAWS, OR AN OPINION OF COUNSEL, REASONABLY SATISFACTORY TO THE COMPANY, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS OR UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT. 
  
 METASOLV, INC. 
  
 WARRANT TO PURCHASE
COMMON STOCK 
  

			
	 Warrant No.: 2
	 	Number of Shares: 250,000
	 Date of Issuance: October 26, 2005
	 	 

  
 THIS IS TO CERTIFY THAT, for value
received, Special Situations Fund III, L.P. or registered assigns (the “Holder”) is entitled to purchase from MetaSolv, Inc., a Delaware corporation (the “Company”), at any time or times on or after April 27,
2006, but not after 5:00 p.m., New York time, on the Expiration Date (as defined herein) at the Exercise Price (as defined herein) Two Hundred Fifty Thousand (250,000) fully paid nonassessable shares of Common Stock (as defined herein) of the
Company (the “Warrant Shares”), all subject to adjustment and upon the terms and conditions as hereinafter provided. This Warrant has been issued pursuant to a Purchase Agreement (as such agreement may be amended from time to time
in accordance therewith, the “Purchase Agreement”) dated as of October 26, 2005, between the initial holder of this Warrant and the Company. 
  
 Section 1. Definitions. 
  
 (a) Definitions. The following words and terms as used in this Warrant shall have the following meanings: 
  
 (i) “Business Day” means any day other than Saturday,
Sunday or other day on which commercial banks in the City of New York are authorized or required by law to remain closed. 
  
 (ii) “Common Stock” means (i) the Company’s common stock, par value $0.005 per share, and (ii) any capital stock into
which such Common Stock shall have been changed or any capital stock resulting from a reclassification of such Common Stock. 
  
 (iii) “Exercise Date” means the date when the Exercise Notice, the Aggregate Exercise Price (as defined below), and the Warrant (or an
indemnification 

 undertaking with respect to the Warrant in the case of its loss, theft or destruction) (the “Exercise Delivery
Documents”) are received by the Company at or prior to 5:00 p.m., New York time, on a Business Day. If any of the Exercise Delivery Documents is received after 5:00 p.m., New York time, on a Business Day, the Exercise Date shall be the next
succeeding Business Day. 
  
 (iv) “Exercise
Price” shall be equal to, with respect to any Warrant Share, $4.00, subject to adjustment as provided herein. 
  
 (v) “Expiration Date” means the date five (5) years after the Initial Issuance Date or, if such date is not a Business Day, the
next succeeding Business Day. 
  
 (vi) “Initial Issuance
Date” means October 26, 2005. 
  
 (vii)
“1933 Act” means the Securities Act of 1933, as amended. 
  
 (viii) “Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization and a government or any department or agency
thereof. 
  
 (ix) “Warrant” means this Warrant
and all Warrants issued in exchange, transfer or replacement thereof. 
  
 (b) Other Definitional Provisions. 
  
 (i) Except
as otherwise specified herein, all references herein (A) to the Company shall be deemed to include the Company’s successors and (B) to any applicable law defined or referred to herein, shall be deemed references to such applicable law
as the same may have been or may be amended or supplemented from time to time. 
  
 (ii) When used in this Warrant, the words “herein,” “hereof,” and “hereunder,” and words of similar import, shall refer to this Warrant as a whole and not to any provision of this
Warrant, and the words “Section,” “Schedule,” and “Exhibit” shall refer to Sections of, and Schedules and Exhibits to, this Warrant unless otherwise specified. 
  
 (iii) Whenever the context so requires, the neuter gender includes the
masculine or feminine, and the singular number includes the plural, and vice versa. 
  
 Section 2. Exercise of Warrant. 
  
 (a) Subject to the terms and conditions hereof, this Warrant may be exercised by the holder hereof then registered on the books of the Company, in whole or in part, at any time on any Business Day on or after the opening of business on
April 27, 2006 and prior to 5:00 p.m., New York time, on the Expiration Date by (i) delivery of a written notice, in the form of the subscription notice attached as Exhibit A hereto (the “Exercise Notice”), of such
holder’s election to exercise this Warrant, which notice shall specify the number of Warrant Shares to be purchased, (ii) payment to the Company of an amount equal to the Exercise Price multiplied by the number of Warrant Shares as to
which this Warrant is being exercised (the “Aggregate 

  

 2 

 
Exercise Price”) in cash or by wire transfer of immediately available funds and (iii) the delivery to the Company of this Warrant (or an
indemnification undertaking with respect to this Warrant in the case of its loss, theft or destruction). 
  
 In the event of any exercise of the rights represented by this Warrant in compliance with this Section 2(a), the Company shall not later than the
second Business Day (the “Warrant Share Delivery Date”) following the Exercise Date, arrange for its transfer agent, on or before the Warrant Share Delivery Date, to issue and surrender to a common carrier for overnight delivery to
the address specified in the Exercise Notice, a certificate, registered in the name of the holder, for the number of shares of Common Stock to which the holder shall be entitled pursuant to such request. Upon delivery of the Exercise Delivery
Documents, the holder of this Warrant shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the
certificates evidencing such Warrant Shares. In the case of a dispute as to the arithmetic calculation of the Warrant Shares, the Company shall promptly issue to the holder the number of shares of Common Stock that is not disputed and shall transmit
an explanation of the disputed arithmetic calculations to the holder via facsimile within one (1) Business Day of the Exercise Date. If the holder and the Company are unable to agree upon the arithmetic calculation of the Warrant Shares within
two (2) Business Days of such disputed arithmetic calculation being transmitted to the holder, then the Company shall within one (1) Business Day transmit via facsimile the disputed arithmetic calculation of the Warrant Shares to its
independent, outside accountant. The Company shall cause the accountant to perform the calculations and notify the Company and the holder of the results no later than forty-eight (48) hours, but at least one (1) Business Day, from the time
it receives the disputed calculations. Such accountant’s calculation shall be deemed conclusive absent manifest error. 
  
 (b) Unless the rights represented by this Warrant shall have expired or shall have been fully exercised, the Company shall, as soon as practicable and in
no event later than five (5) Business Days after the Exercise Date and at its own expense, issue a new Warrant identical in all respects to this Warrant except it shall represent rights to purchase the number of Warrant Shares purchasable
immediately prior to such exercise under this Warrant exercised, less the number of Warrant Shares with respect to which this Warrant is exercised. 
  
 (c) No fractional shares of Common Stock are to be issued upon the exercise of this Warrant, but rather the number of shares of Common Stock issued upon
exercise of this Warrant shall be rounded up or down to the nearest whole number. 
  
 Section 3. Company Call Right. Notwithstanding any other provision contained in this Warrant to the contrary, in the event that the closing bid price per share of Common Stock as quoted on the Nasdaq National
Market (or such other exchange or stock market on which the Common Stock may then be listed or quoted) equals or exceeds $7.00 (appropriately adjusted for any stock split, reverse stock split, stock dividend or other reclassification or combination
of the Common Stock occurring after the date hereof) for twenty (20) consecutive trading days commencing on or after the later of (a) the Registration Statement (as defined in the Purchase Agreement) having been declared effective and
(b) six (6) months after the Initial Issuance Date, the Company, upon thirty (30) days prior written notice (the “Notice Period”) given to the Holder within five (5) Business Days immediately following the end of
such twenty (20) trading 

  

 3 

 
day period, may call this Warrant, in whole or in part, at a redemption price equal to $0.01 per share of Common Stock then purchasable pursuant to this
Warrant; provided that (i) the Company simultaneously calls all, or an equal percentage, of the Warrants originally issued to the Other Purchasers (as defined in the Purchase Agreement) on the same terms, and (ii) all of the shares of
Common Stock issuable hereunder are registered pursuant to an effective Registration Statement (as defined in the Purchase Agreement) which is not suspended and for which no stop order is in effect, and pursuant to which the Holder is able to sell
such shares of Common Stock at all times during the Notice Period. Notwithstanding any such notice by the Company, the Holder shall have the right to exercise this Warrant prior to the end of the Notice Period. 
  
 Section 4. Covenants as to Common Stock. The Company hereby covenants
and agrees as follows: 
  
 (a) This Warrant is, and any Warrants
issued in substitution for or replacement of this Warrant upon issuance will be, duly authorized and validly issued. 
  
 (b) All Warrant Shares which may be issued upon the exercise of the rights represented by this Warrant upon issuance will be validly issued, fully paid
and nonassessable (assuming payment of the Exercise Price) and free from all taxes, liens and charges with respect to the issue thereof. 
  
 (c) During the period within which the rights represented by this Warrant may be exercised, the Company will at all times have authorized and reserved at
least 100% of the number of shares of Common Stock needed to provide for the exercise of the rights then represented by this Warrant and the par value of said shares will at all times be less than or equal to the applicable Exercise Price.

  
 (d) The Company shall promptly secure the listing of the
shares of Common Stock issuable upon exercise of this Warrant upon each national securities exchange or automated quotation system, if any, upon which shares of Common Stock are then listed (subject to official notice of issuance upon exercise of
this Warrant) and shall maintain, so long as any other shares of Common Stock shall be so listed, such listing of all shares of Common Stock from time to time issuable upon the exercise of this Warrant; and the Company shall so list on each national
securities exchange or automated quotation system, as the case may be, and shall maintain such listing of, any other shares of capital stock of the Company issuable upon the exercise of this Warrant if and so long as any shares of the same class
shall be listed on such national securities exchange or automated quotation system. 
  
 (e) The Company will not, by amendment of its Certificate of Incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities, or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed by it hereunder, but will at all times in good faith assist in the carrying out of all the provisions of this Warrant and in the taking of
all such action as may reasonably be requested by the holder of this Warrant in order to protect the exercise privilege of the holder of this Warrant against dilution or other impairment, consistent with the tenor and purpose of this Warrant.
Without limiting the generality of the foregoing, the 

  

 4 

 
Company (i) will not increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in
effect, and (ii) will take all such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant. 
  
 (f) This Warrant will be binding upon any entity succeeding to the Company by
merger, consolidation or acquisition of all or substantially all of the Company’s assets. 
  
 Section 5. Taxes. The Company shall pay any and all documentary stamp taxes which may be payable with respect to the issuance and delivery of Warrant Shares upon exercise of this Warrant. 
  
 Section 6. Warrant Holder Not Deemed a Stockholder. Except as
otherwise specifically provided herein, no holder, as such, of this Warrant shall be entitled to vote or receive dividends or be deemed the holder of shares of the Company for any purpose, nor shall anything contained in this Warrant be construed to
confer upon the holder hereof, as such, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation,
merger, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the holder of this Warrant of the Warrant Shares which he or she is then entitled to receive upon the due
exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on such holder to purchase any securities or as a stockholder of the Company, whether such liabilities are asserted by the
Company or by creditors of the Company. 
  
 Section 7.
Representations of Holder. The holder of this Warrant, by the acceptance hereof, represents that it is acquiring this Warrant and the Warrant Shares for its own account for investment only and not with a view towards, or for resale in
connection with, the public sale or distribution of this Warrant or the Warrant Shares, except pursuant to sales registered or exempted under the 1933 Act. The holder of this Warrant further represents, by acceptance hereof, that, as of this date,
and as of the date of any exercise of this Warrant, such holder is an “accredited investor” as such term is defined in Rule 501(a)(1) of Regulation D promulgated by the Securities and Exchange Commission under the 1933 Act (an
“Accredited Investor”). 
  
 Section 8.
Ownership and Transfer. 
  
 (a) The Company shall maintain
at its principal executive offices (or such other office or agency of the Company as it may designate by notice to the holder hereof), a register for this Warrant, in which the Company shall record the name and address of the Person in whose name
this Warrant has been issued, as well as the name and address of each transferee. The Company may treat the Person in whose name any Warrant is registered on the register as the owner and holder thereof for all purposes, notwithstanding any notice
to the contrary, but in all events recognizing any transfers made in accordance with the terms of this Warrant. 
  
 (b) This Warrant may be offered for sale, sold, transferred or assigned without the consent of the Company, except as may otherwise be required by the
Purchase Agreement. 
  

 5 

 (c) The Company is obligated to register the Warrant Shares for resale under the 1933 Act pursuant to the
Purchase Agreement and the holder of this Warrant is entitled to the registration rights in respect of the Warrant Shares as set forth in the Purchase Agreement. 
  
 Section 9. Adjustment of Exercise Price and Number of Shares. The Exercise Price and the number of shares of Common
Stock issuable upon exercise of this Warrant shall be adjusted from time to time as follows: 
  
 (a) If the Company shall, at any time or from time to time while this Warrant is outstanding, (i) pay a dividend or make a distribution on its Common Stock in shares of Common Stock, (ii) subdivide its
outstanding shares of Common Stock into a greater number of shares or (iii) combine its outstanding shares of Common Stock into a smaller number of shares or issue by reclassification of its outstanding shares of Common Stock any shares of its
capital stock (including any such reclassification in connection with a consolidation or merger in which the Company is the continuing corporation), then the number of Warrant Shares purchasable upon exercise of the Warrant and the Exercise Price in
effect immediately prior to the date upon which such change shall become effective, shall be adjusted by the Company so that the Holder thereafter exercising the Warrant shall be entitled to receive the number of shares of Common Stock or other
capital stock which the Holder would have received if the Warrant had been exercised immediately prior to such event upon payment of the Exercise Price that has been adjusted to reflect a fair allocation of the economics of such event to the Holder.
Such adjustments shall be made successively whenever any event listed above shall occur. 
  
 (b) If any capital reorganization or reclassification of the capital stock of the Company (other than subdivisions, combinations or reclassifications covered by Section 9(a) or a change in par value), or
consolidation or merger of the Company with another corporation in which the Company is not the survivor, or sale, transfer (other than a pledge, mortgage or hypothecation to a lender as security for a bona fide loan) or other disposition of all or
substantially all of the Company’s assets to another corporation shall be effected (in any such case, a “Fundamental Transaction”), then, as a condition of such Fundamental Transaction, lawful and adequate provision shall be
made whereby the Holder shall thereafter have the right to purchase and receive upon the basis and upon the terms and conditions herein specified and in lieu of the Warrant Shares immediately theretofore issuable upon exercise of the Warrant, such
shares of stock, securities or assets as would have been issuable or payable with respect to or in exchange for a number of Warrant Shares equal to the number of Warrant Shares immediately theretofore issuable upon exercise of the Warrant, had such
Fundamental Transaction not taken place, and in any such case appropriate provision shall be made with respect to the rights and interests of the Holder to the end that the provisions hereof (including, without limitation, provision for adjustment
of the Exercise Price) shall thereafter be applicable, as nearly equivalent as may be practicable in relation to any shares of stock, securities or assets thereafter deliverable upon the exercise hereof. The Company shall not effect any such
consolidation, merger, sale, transfer or other disposition unless prior to or simultaneously with the consummation thereof the successor corporation (if other than the Company) resulting from such consolidation or merger, or the corporation
purchasing or otherwise acquiring such assets or other appropriate corporation or entity shall assume the obligation to deliver to the Holder, at the last address of the Holder appearing on the books of the Company, such shares of stock, securities
or assets as, in accordance with the foregoing provisions, the Holder may be entitled to purchase, and the other 

  

 6 

 
obligations under this Warrant. The provisions of this paragraph (b) shall similarly apply to successive reorganizations, reclassifications,
consolidations, mergers, sales, transfers or other dispositions. 
  
 (c) In case the Company shall fix a payment date for the making of a distribution to all holders of Common Stock (including any such distribution made in connection with a consolidation or merger in which the Company is the continuing
corporation) of (i) evidences of indebtedness or assets (other than cash dividends or cash distributions payable out of consolidated earnings or earned surplus or dividends or distributions referred to in Section 9(a)), or
(ii) subscription rights or warrants, the Exercise Price to be in effect after such payment date shall be determined by multiplying the Exercise Price in effect immediately prior to such payment date by a fraction, the numerator of which shall
be the total number of shares of Common Stock outstanding multiplied by the Market Price (as defined below) per share of Common Stock immediately prior to such payment date, less the fair market value (as determined by the Company’s Board of
Directors in good faith) of said assets or evidences of indebtedness so distributed, or of such subscription rights or warrants, and the denominator of which shall be the total number of shares of Common Stock outstanding multiplied by the Market
Price per share of Common Stock immediately prior to such payment date. “Market Price” as of a particular date (the “Valuation Date”) shall mean the following: (a) if the Common Stock is then listed on a
national stock exchange, the closing sale price of one share of Common Stock on such exchange on the last trading day prior to the Valuation Date; (b) if the Common Stock is then quoted on The Nasdaq Stock Market, Inc.
(“Nasdaq”), the National Association of Securities Dealers, Inc. OTC Bulletin Board (the “Bulletin Board”) or such similar quotation system or association, the closing sale price of one share of Common Stock on
Nasdaq, the Bulletin Board or such other quotation system or association on the last trading day prior to the Valuation Date or, if no such closing sale price is available, the average of the high bid and the low asked price quoted thereon on the
last trading day prior to the Valuation Date; or (c) if the Common Stock is not then listed on a national stock exchange or quoted on Nasdaq, the Bulletin Board or such other quotation system or association, the fair market value of one share
of Common Stock as of the Valuation Date, as determined in good faith by the Board of Directors of the Company and the Holder as hereinafter provided in this paragraph. If the Common Stock is not then listed on a national securities exchange, the
Bulletin Board or such other quotation system or association, the Board of Directors of the Company shall respond promptly, in writing, to an inquiry by the Holder prior to the exercise hereunder as to the fair market value of a share of Common
Stock as determined by the Board of Directors of the Company. In the event that the Board of Directors of the Company and the Holder are unable to agree upon the fair market value in respect of subpart (c) of this paragraph, the Company and the
Holder shall jointly select an appraiser, who is experienced in such matters. The decision of such appraiser shall be final and conclusive, and the cost of such appraiser shall be borne equally by the Company and the Holder. Such adjustment shall be
made successively whenever such a payment date is fixed. 
  
 (d)
An adjustment to the Exercise Price shall become effective immediately after the payment date in the case of each dividend or distribution and immediately after the effective date of each other event which requires an adjustment. 
  

 7 

 (e) In the event that, as a result of an adjustment made pursuant to this Section 9, the Holder
shall become entitled to receive any shares of capital stock of the Company other than shares of Common Stock, the number of such other shares so receivable upon exercise of this Warrant shall be subject thereafter to adjustment from time to time in
a manner and on terms as nearly equivalent as practicable to the provisions with respect to the Warrant Shares contained in this Warrant. 
  
 (f) Except as provided in subsection (g) hereof, if and whenever the Company shall issue or sell, or is, in accordance with any of subsections (f)(1)
through (f)(7) hereof, deemed to have issued or sold, any shares of Common Stock for no consideration or for a consideration per share less than the Exercise Price in effect immediately prior to the time of such issue or sale, then and in each such
case (a “Trigger Issuance”) the then-existing Exercise Price, shall be reduced, as of the close of business on the effective date of the Trigger Issuance, to a price determined as follows: 
  

			
	 Adjusted Exercise Price =
	 	(A x B) + D
	 	 	      A+C      

  
 where 
  
 “A” equals the number of shares of Common Stock outstanding,
including Additional Shares of Common Stock (as defined below) deemed to be issued hereunder, immediately preceding such Trigger Issuance; 
  
 “B” equals the Exercise Price in effect immediately preceding such Trigger Issuance; 
  
 “C” equals the number of Additional Shares of Common Stock issued
or deemed issued hereunder as a result of the Trigger Issuance; and 
  
 “D” equals the aggregate consideration, if any, received or deemed to be received by the Company upon such Trigger Issuance; 
  
 provided, however, that in no event shall the Exercise Price after giving effect to such Trigger Issuance be greater than the Exercise Price in effect prior to such
Trigger Issuance. 
  
 For purposes of this subsection (f),
“Additional Shares of Common Stock” shall mean all shares of Common Stock issued by the Company or deemed to be issued pursuant to this subsection (f), other than Excluded Issuances (as defined in subsection (g) hereof).

  
 For purposes of this subsection (f), the following subsections
(f)(1) to (f)(8) shall also be applicable: 
  
 (f) (1) Issuance
of Rights or Options. In case at any time the Company shall in any manner grant (directly and not by assumption in a merger or otherwise) any warrants or other rights to subscribe for or to purchase, or any options for the purchase of, Common
Stock or any stock or security convertible into or exchangeable for Common Stock (such warrants, rights or options being called “Options” and such convertible or exchangeable stock or securities being 

  

 8 

 
called “Convertible Securities”) whether or not such Options or the right to convert or exchange any such Convertible Securities are
immediately exercisable, and the price per share for which Common Stock is issuable upon the exercise of such Options or upon the conversion or exchange of such Convertible Securities (determined by dividing (i) the sum (which sum shall
constitute the applicable consideration) of (x) the total amount, if any, received or receivable by the Company as consideration for the granting of such Options, plus (y) the aggregate amount of additional consideration payable to the
Company upon the exercise of all such Options, plus (z), in the case of such Options which relate to Convertible Securities, the aggregate amount of additional consideration, if any, payable upon the issue or sale of such Convertible Securities and
upon the conversion or exchange thereof, by (ii) the total maximum number of shares of Common Stock issuable upon the exercise of such Options or upon the conversion or exchange of all such Convertible Securities issuable upon the exercise of
such Options) shall be less than the Exercise Price in effect immediately prior to the time of the granting of such Options, then the total number of shares of Common Stock issuable upon the exercise of such Options or upon conversion or exchange of
the total amount of such Convertible Securities issuable upon the exercise of such Options shall be deemed to have been issued for such price per share as of the date of granting of such Options or the issuance of such Convertible Securities and
thereafter shall be deemed to be outstanding for purposes of adjusting the Exercise Price. Except as otherwise provided in subsection 9(f)(3), no further adjustment of the Exercise Price shall be made upon the actual issue of such Common Stock or of
such Convertible Securities upon exercise of such Options or upon the actual issue of such Common Stock upon conversion or exchange of such Convertible Securities. 
  
 (f) (2) Issuance of Convertible Securities. In case the Company shall in any manner issue (directly and not by
assumption in a merger or otherwise) or sell any Convertible Securities, whether or not the rights to exchange or convert any such Convertible Securities are immediately exercisable, and the price per share for which Common Stock is issuable upon
such conversion or exchange (determined by dividing (i) the sum (which sum shall constitute the applicable consideration) of (x) the total amount received or receivable by the Company as consideration for the issue or sale of such
Convertible Securities, plus (y) the aggregate amount of additional consideration, if any, payable to the Company upon the conversion or exchange thereof, by (ii) the total maximum number of shares of Common Stock issuable upon the
conversion or exchange of all such Convertible Securities) shall be less than the Exercise Price in effect immediately prior to the time of such issue or sale, then the total number of shares of Common Stock issuable upon conversion or exchange of
all such Convertible Securities shall be deemed to have been issued for such price per share as of the date of the issue or sale of such Convertible Securities and thereafter shall be deemed to be outstanding for purposes of adjusting the Exercise
Price, provided that (a) except as otherwise provided in subsection 9(f)(3), no further adjustment of the Exercise Price shall be made upon the actual issuance of such Common Stock upon conversion or exchange of such Convertible Securities and
(b) no further adjustment of the Exercise Price shall be made by reason of the issue or sale of Convertible Securities upon exercise of any Options to purchase any such Convertible Securities for which adjustments of the Exercise Price have
been made pursuant to the other provisions of subsection 9(f). 
  
 (f) (3) Change in Option Price or Conversion Rate. Upon the happening of any of the following events, namely, (i) if the purchase price provided for in any Option referred to in subsection 9(f)(1) hereof, (ii) the
additional consideration, if any, payable upon the conversion or 

  

 9 

 
exchange of any Convertible Securities referred to in subsections 9(f)(1) or 9(f)(2), or (iii) the rate at which Convertible Securities referred to in
subsections 9(f)(1) or 9(f)(2) are convertible into or exchangeable for Common Stock shall change at any time (including, but not limited to, changes under or by reason of provisions designed to protect against dilution), then the Exercise Price in
effect at the time of such event shall be readjusted to the Exercise Price which would have been in effect at such time had such Options or Convertible Securities still outstanding provided for such changed purchase price, additional consideration
or conversion rate, as the case may be, at the time initially granted, issued or sold. On the expiration or termination of any Option for which any adjustment was made pursuant to this subsection 9(f) or any right to convert or exchange Convertible
Securities for which any adjustment was made pursuant to this subsection 9(f) (including without limitation upon the redemption or purchase for consideration of such Convertible Securities by the Company), the Exercise Price then in effect hereunder
shall forthwith be changed to the Exercise Price which would have been in effect at the time of such termination had such Option or Convertible Securities, to the extent outstanding immediately prior to such termination, never been issued.

  
 (f) (4) Stock Dividends. Subject to the provisions of
this Section 9(f), in case the Company shall declare a dividend or make any other distribution upon any capital stock of the Company (other than the Common Stock) payable in Common Stock, Options or Convertible Securities, then any Common
Stock, Options or Convertible Securities, as the case may be, issuable in payment of such dividend or distribution shall be deemed to have been issued or sold without consideration. 
  
 (f) (5) Consideration for Stock. In case any shares of Common Stock, Options or Convertible Securities shall be
issued or sold for cash, the consideration received therefor shall be deemed to be the net amount received by the Company therefor, after deduction therefrom of any expenses incurred or any underwriting commissions or concessions paid or allowed by
the Company in connection therewith. In case any shares of Common Stock, Options or Convertible Securities shall be issued or sold for a consideration other than cash, including in the case of a strategic or similar arrangement in which the other
entity will provide services to the Company, purchase services from the Company or otherwise provide intangible consideration to the Company, the amount of the consideration other than cash received by the Company (including the net present value of
the consideration other than cash expected by the Company for the provided or purchased services) shall be deemed to be the fair value of such consideration as determined in good faith by the Board of Directors of the Company, after deduction of any
expenses incurred or any underwriting commissions or concessions paid or allowed by the Company in connection therewith. In case any Options shall be issued in connection with the issue and sale of other securities of the Company, together
comprising one integral transaction in which no specific consideration is allocated to such Options by the parties thereto, such Options shall be deemed to have been issued for such consideration as determined in good faith by the Board of Directors
of the Company. If Common Stock, Options or Convertible Securities shall be issued or sold by the Company and, in connection therewith, other Options or Convertible Securities (the “Additional Rights”) are issued, then the
consideration received or deemed to be received by the Company shall be reduced by the fair market value of the Additional Rights (as determined using the Black-Scholes option pricing model or another method mutually agreed to by the Board of
Directors of the Company and the Holder as hereinafter provided in this paragraph). The Board of Directors of the Company shall respond promptly, in writing, to an 

  

 10 

 
inquiry by the Holder as to the fair market value of the Additional Rights. In the event that the Board of Directors of the Company and the Holder are unable
to agree upon the fair market value of the Additional Rights, the Company and the Holder shall jointly select an appraiser, who is experienced in such matters. The decision of such appraiser shall be final and conclusive, and the cost of such
appraiser shall be borne evenly by the Company and the Holder. 
  
 (f) (6) Record Date. In case the Company shall take a record of the holders of its Common Stock for the purpose of entitling them (i) to receive a dividend or other distribution payable in Common Stock, Options or
Convertible Securities or (ii) to subscribe for or purchase Common Stock, Options or Convertible Securities, then such record date shall be deemed to be the date of the issue or sale of the shares of Common Stock deemed to have been issued or
sold upon the declaration of such dividend or the making of such other distribution or the date of the granting of such right of subscription or purchase, as the case may be; provided, however, that if before the distribution to its holders of
Common Stock the Company legally abandons it plan to pay or deliver such dividend, distribution, subscription or purchase rights, then thereafter no adjustment shall be required by the taking of such record and any such adjustment previously made in
respect thereof shall be rescinded and annulled. 
  
 (f)
(7) Treasury Shares. The number of shares of Common Stock outstanding at any given time shall not include shares owned or held by or for the account of the Company or any of its wholly-owned subsidiaries, and the disposition of any such
shares (other than the cancellation or retirement thereof or the transfer of such shares among the Company and its wholly-owned subsidiaries) shall be considered an issue or sale of Common Stock for the purpose of this subsection (f). 
  
 (f) (8) Nasdaq Limitation. Notwithstanding any other provision in
Section 9(f) to the contrary, for so long as this Warrant is outstanding, if a reduction in the Exercise Price pursuant to Section 9(f) (other than as set forth in this clause (f)(8)) would require the Company to obtain stockholder
approval of the transactions contemplated by the Purchase Agreement pursuant to Nasdaq Marketplace Rule 4350(i) and such stockholder approval has not been obtained, (i) the Exercise Price shall be reduced to the maximum extent that would not
require stockholder approval under such Rule, and (ii) the Company shall use its commercially reasonable efforts to obtain such stockholder approval as soon as reasonably practicable, including by calling a special meeting of stockholders to
vote on such Exercise Price adjustment. This provision shall not restrict the number of shares of Common Stock which a holder may receive or beneficially own in order to determine the amount of securities or other consideration that such holder may
receive in the event of a transaction contemplated by Section 9 of this Warrant. 
  
 (g) Anything herein to the contrary notwithstanding, the Company shall not be required to make any adjustment of the Exercise Price in the case of the issuance of (A) capital stock, Options or Convertible
Securities issued to directors, officers, employees or consultants of the Company in connection with their service as directors of the Company, their employment by the Company or their retention as consultants by the Company pursuant to an equity
compensation program approved by the Board of Directors of the Company or the compensation committee of the Board of Directors of the Company, (B) shares of Common Stock issued upon the conversion or exercise of Options or Convertible
Securities issued prior to 

  

 11 

 
the date hereof, provided such securities are not amended after the date hereof to increase the number of shares of Common Stock issuable thereunder or to
lower the exercise or conversion price thereof, (C) securities issued pursuant to the Purchase Agreement or purchase agreements of the same form as the Purchase Agreement between the Company and the Other Purchasers (as defined in the Purchase
Agreement) and securities issued upon the exercise or conversion of those securities, (D) securities issued pursuant to the exercise of this Warrant or warrants in the same form as this Warrant and issued to the Other Purchasers,
(E) capital stock, Options or Convertible Securities issued (i) to persons in connection with a joint venture, strategic alliance or other commercial relationship with such person (including persons who are customers, suppliers and
strategic partners of the Company) relating to the operation of the Company’s or its subsidiaries’ business and not for the primary purpose of raising equity capital, or (ii) in connection with a transaction in which the Company,
directly or indirectly, acquires another business or its tangible or intangible assets (an “Acquisition Transaction”), excluding Acquisition Transactions in which cash or cash equivalents represent more than 20% of the assets
acquired, (F) Common Stock to employees pursuant to any employee stock purchase program, (G) Common Stock or common stock equivalents in an offering for cash for the account of the Company that is underwritten on a firm commitment basis
and is registered with the Securities and Exchange Commission under the 1933 Act, (H) capital stock, Options or Convertible Securities issued to the lessor or vendor in any office lease or equipment lease or similar equipment financing
transaction in which the Company or any subsidiary obtains the use of such office space or equipment for its business, or (I) shares of Common Stock issued or issuable by reason of a dividend, stock split or other distribution on shares of
Common Stock (but only to the extent that such a dividend, split or distribution results in an adjustment in the Exercise Price pursuant to the other provisions of this Warrant) (collectively, “Excluded Issuances”). 
  
 (h) Upon any adjustment to the Exercise Price pursuant to Section 9(f)
above, the number of Warrant Shares purchasable hereunder shall be adjusted by multiplying such number by a fraction, the numerator of which shall be the Exercise Price in effect immediately prior to such adjustment and the denominator of which
shall be the Exercise Price in effect immediately thereafter. 
  
 (i) Notices. Immediately upon any adjustment of the Exercise Price, the Company will give written notice thereof to the holder of this Warrant, setting forth in reasonable detail, and certifying, the calculation of such adjustment.

  
 Section 10. Lost, Stolen, Mutilated or Destroyed
Warrant. If this Warrant is lost, stolen, mutilated or destroyed, the Company shall promptly, on receipt of an indemnification undertaking (or, in the case of a mutilated Warrant, the Warrant), issue a new Warrant of like denomination and tenor
as this Warrant so lost, stolen, mutilated or destroyed. 
  
 Section 11. Notice. All notices, requests, consents, waivers or other communications hereunder shall be in writing and shall be deemed effectively given: (a) upon delivery to the party to be notified, (b) when received
by confirmed facsimile or (c) one (1) Business Day after deposit with a nationally recognized overnight courier, specifying next business day delivery, with written verification of receipt, provided that, with respect to Exercise Delivery
Documents, such documents shall not be deemed received until actually received by the recipient. All 

  

 12 

 
notices, requests, consents, waivers or other communications shall be sent to the Company or to the Holder as follows or at such other addresses as the
Company or Holder may designate upon written notice to the other party: 
  
 If to the Company: 
  
 MetaSolv,
Inc. 
 5556 Tennyson Parkway 
 Plano, TX 75024 
 Facsimile: (972) 403-8989 
 Attention: Chief Financial Officer 
  
 With a copy to: 
  
 MetaSolv,
Inc. 
 5556 Tennyson Parkway 
 Plano, TX 75024 
 Facsimile: (972) 403-8989 
 Attention: Jonathan K. Hustis 
  
 With a copy to: 
  
 Vinson &
Elkins L.L.P. 
 3700 Trammell Crow Center 
 2001 Ross Avenue 
 Dallas, TX 75201-2975 
 Facsimile: (214) 220-7716 
 Attention:
Jeffrey A. Chapman, Esq. 
  
 If to the holder of this Warrant, to it at the
address and facsimile number set forth on Appendix I to the Purchase Agreement or at such other address and facsimile as shall be delivered to the Company upon the issuance or transfer of this Warrant. 
  
 Section 12. [Reserved]. 
  
 Section 13. Remedies, Other Obligations, Breaches and Injunctive
Relief. The remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant and the Purchase Agreement, at law or in equity (including a decree of specific performance and/or other
injunctive relief), and nothing herein shall limit the right of the holder of this Warrant right to pursue actual damages for any failure by the Company to comply with the terms of this Warrant. The Company acknowledges that a breach by it of its
obligations hereunder will cause irreparable harm to the holder of this Warrant and that the remedy at law for any such breach may be inadequate. The Company therefore agrees that, in the event of any such breach or threatened breach, the holder of
this Warrant shall be entitled, in addition to all other available remedies, to an injunction restraining any breach, without the necessity of showing economic loss and without any bond or other security being required. 
  

 13 

 Section 14. Amendment and Waiver. Except as otherwise provided herein, this Warrant may not
be modified or amended except pursuant to an instrument in writing signed by the Company and the holder of the Warrant. No provision hereunder may be waived other than in a written instrument executed by the waiving party. 
  
 Section 15. Governing Law; Jurisdiction; Service of Process. This
Warrant shall be governed by and construed in accordance with the laws of the State of New York and the federal law of the United States of America. Any action or proceeding seeking to enforce any provision of, or based on any right arising out of,
this Warrant shall be brought against any of the parties in the courts of the State of New York, County of New York, or, if it has or can acquire jurisdiction, in the United States District Court of the Southern District of New York, and each of the
parties consents to the jurisdiction of such courts (and of the appropriate appellate courts) in any such action or proceeding and waives any objection to venue laid therein. Process in any action or proceeding referred to in the preceding sentence
may be served on any party anywhere in the world. 
  
 Section 16. Construction; Headings. This Warrant shall be deemed to be jointly drafted by the Company and the Purchaser (as defined in the Purchase Agreement) and shall not be construed against any person as the drafter hereof.
The headings of this Warrant are for convenience of reference and shall not form part of, or affect the interpretation of, this Warrant. 
  
 Section 17. Cashless Exercise. Notwithstanding any other provision contained herein to the contrary, from and after the first anniversary of
the Closing Date (as defined in the Purchase Agreement), if the Warrant Shares may not be freely sold to the public for any reason (including, but not limited to, the failure of the Company to have effected the registration of the Warrant Shares or
to have a current prospectus available for delivery or otherwise, but excluding the period of any allowed Suspension (as defined in the Purchase Agreement)), the holder may elect to receive, without the payment by the holder of the aggregate
Exercise Price in respect of the shares of Common Stock to be acquired, shares of Common Stock of equal value to the value of this Warrant, or any specified portion hereof, by the surrender of this Warrant (or such portion of this Warrant being so
exercised) together with a Net Issue Election Notice, in the form annexed hereto as Appendix B, duly executed, to the Company (the “Cashless Exercise Right”). Thereupon, the Company shall issue to the holder such number of fully
paid, validly issued and nonassessable shares of Common Stock as is computed using the following formula: 
  
 X = Y (A - B) 
      A 
  
 where 
  
 X = the number of shares of Common Stock to which the holder is entitled
upon such cashless exercise; 
  
 Y = the total number of shares
of Common Stock covered by this Warrant for which the holder has surrendered purchase rights at such time for cashless exercise (including both shares to be issued to the holder and shares as to which the purchase rights are to be canceled as
payment therefor); 
  

 14 

 A = the “Market Price” of one share of Common Stock as at the date the net issue election is
made; and 
  
 B = the Exercise Price in effect under this Warrant
at the time the net issue election is made. 
  
 Notwithstanding the foregoing, the
holder shall be entitled to exercise the Cashless Exercise Right at the time of the exercise of the Company’s call right set forth in Section 3 hereof during the entire Notice Period. 
  
 [Signature Page Follows] 
  

 15 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be signed as of the
         day of             , 2005. 
  

			
	 METASOLV, INC.

		
	 By:
	 	  

	 	 	 Name:

	 	 	 Title:

 EXHIBIT A TO WARRANT 
  
 SUBSCRIPTION FORM 
  
 TO BE EXECUTED BY THE REGISTERED HOLDER 
 TO
EXERCISE THIS WARRANT 
  
 METASOLV, INC. 
  
 The undersigned Holder hereby exercises the right to purchase
             of the shares of Common Stock (“Warrant Shares”) of MetaSolv, Inc., a Delaware corporation (the “Company”), evidenced by the attached
Warrant (the “Warrant”). Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant. 
  

The undersigned Holder hereby represents and warrants to, and covenants with, the Company that: (a) the Holder is knowledgeable, sophisticated and
experienced in making, and is qualified to make, decisions with respect to investments in securities representing an investment decision like that involved in the purchase of the Warrant Shares, including investments in securities issued by the
Company and comparable entities, and has requested, received, reviewed and considered all information it deems relevant in making an informed decision to purchase the Warrant Shares; (b) the Holder is acquiring the Warrant Shares set forth
above in the ordinary course of its business and for its own account for investment only and with no present intention or view to the public sale or distribution of any of such Warrant Shares, and no arrangement or understanding exists with any
other persons regarding the public sale or distribution of such Warrant Shares, except as contemplated by the Registration Statement without prejudice, however, to such Purchaser’s right at all times to sell or otherwise dispose of all or any
part of such Warrant Shares in compliance with applicable federal and state securities laws; and provided, however, that nothing contained herein shall be deemed a representation or warranty by such Purchaser to hold the Warrant Shares for any
period of time; and (c) the Holder is an “accredited investor” within the meaning of Rule 501(a) of Regulation D promulgated under the 1933 Act. 
  

1. Payment of Exercise Price. The Holder shall pay the sum of $             to the
Company in accordance with the terms of the Warrant. 
  
 2.
Delivery of Warrant Shares. The Company shall deliver to the Holder              Warrant Shares in accordance with the terms of the Warrant. 
  

			
	 Date: _______________ __, ______

		
	 By:
	 	  

	 	 	 Name:

	 	 	 Title:

 ACKNOWLEDGMENT 
  
 The Company hereby acknowledges this Exercise Notice and hereby directs
            . to issue the above indicated number of shares of Common Stock in accordance with the Transfer Agent Instructions dated
            , 2005 from the Company and acknowledged and agreed to by             . 
  

			
	 METASOLV, INC.

		
	 By:
	 	  

	 	 	 Name:

	 	 	 Title:

 APPENDIX B 
 METASOLV, INC. 
 NET ISSUE ELECTION NOTICE 
  
 To: MetaSolv, Inc. 
  

Date:[            ] 
  
 The undersigned hereby elects under Section 17 of this Warrant
to surrender the right to purchase [            ] shares of Common Stock pursuant to this Warrant and hereby requests the issuance of
[            ] shares of Common Stock. The certificate(s) for the shares issuable upon such net issue election shall be issued in the name of the undersigned or as otherwise
indicated below. 
  

			
	  

 Signature
  

 Name for Registration
  

 Mailing AddressPurchase Agreement

 Exhibit 10.1 
  
 EXECUTION VERSION 
  
 PURCHASE AGREEMENT 
  
 THIS AGREEMENT (this “Agreement”) is made as of the 26th day of October, 2005, by and between MetaSolv, Inc. (the “Company”), a
corporation organized under the laws of the State of Delaware, with its principal offices at 5556 Tennyson Parkway, Plano, TX 75024, and the purchaser whose name and address are set forth on the signature page hereof (the “Purchaser”).

  
 RECITALS 
  
 WHEREAS, the Company desires to issue and sell shares of the Company’s
Common Stock and Warrants (each as defined in SECTION 1) in a private placement (the “Offering”); 
  
 WHEREAS, in furtherance of the Offering, the Purchaser has reviewed the Exchange Act Filings (as defined in SECTION 4.18); 
  
 WHEREAS, the Purchaser desires, upon the terms and conditions of this
Agreement, to purchase shares of the Company’s Common Stock and Warrants in the Offering; and 
  
 WHEREAS, the Company and the Purchaser are executing and delivering this Agreement in reliance upon exemptions from registration of this Offering afforded
by Section 4(2) of the Securities Act (as defined in SECTION 3), Rule 506 promulgated under the Securities Act, and such other exemptions as the Company may determine applicable. 
  
 NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, the Company and the Purchaser agree as
follows: 
  
 SECTION 1. Authorization of Sale of the
Securities. Subject to the terms and conditions of this Agreement, the Company has authorized the issuance and sale in the Offering of (a) up to 8,000,000 shares (the “Shares”) of common stock, par value $0.005 per share (the
“Common Stock”), of the Company and (b) warrants (the “Warrants”) to purchase up to 4,000,000 shares of common stock (the “Warrant Shares”) at an initial exercise price of $4.00 per share, subject to adjustment,
evidenced by a warrant certificate in the form attached hereto as Exhibit A (the “Warrant Certificate”). The Company reserves the right to increase or decrease the number of Shares and Warrant Shares sold in the Offering prior to the
Closing Date (as defined in SECTION 3); provided, however, that the minimum amount sold shall be no less than $9,000,000 and the maximum amount sold shall be no more than $24,000,000. The Shares, the Warrants and the Warrant Shares are hereinafter
sometimes referred to together as the “Securities,” and each Share plus one-half of a Warrant is hereinafter referred to as a “Unit.” 
  
 SECTION 2. Agreement to Sell and Purchase the Securities. At the Closing (as defined in SECTION 3), the Company will issue and sell to the
Purchaser, and the Purchaser will buy from the Company, upon the terms and conditions hereinafter set forth, the number of Securities shown below at the purchase price shown below: 
  

									
	 Shares to
 be Purchased

	 	Warrants

	 	Price Per Unit in
Dollars

	 	Aggregate
Price

	 	 	 	 	$	3.00	 	$	 

 The Company has entered into, or proposes to enter into, purchase agreements in the same form with
certain other investors (the “Other Purchasers”) and expects to complete sales of the Securities to them as part of the Offering at the same per Unit purchase price set forth above. The Purchaser and the Other Purchasers are hereinafter
sometimes collectively referred to as the “Purchasers,” and this Agreement and the agreements executed by the Other Purchasers are hereinafter sometimes collectively referred to as the “Agreements,” and the Warrant Certificate
and the warrant certificates delivered by the Company to the Other Purchasers are hereinafter sometimes collectively referred to as the “Warrant Certificates.” The Agreements and the Warrant Certificates are hereinafter sometimes together
referred to as the “Transaction Documents.” The term “Placement Agent” shall mean Raymond James & Associates, Inc. 
  
 SECTION 3. Delivery of the Securities at the Closing. The completion of the purchase and sale of the Shares and the Warrants (the
“Closing”) is occurring concurrently with the execution hereof at the offices of Morrison & Foerster LLP, 1290 Avenue of the Americas, New York, New York 10104 (the “Closing Date”). 
  
 Concurrently with the execution hereof, the Company is delivering to the
Purchaser (a) one or more stock certificates representing the number of Shares set forth in SECTION 2, (b) one or more Warrant Certificates representing the number of Warrants set forth in SECTION 2 above, each registered in the name of
the Purchaser, or, if so indicated on the Securities Certificate Questionnaire attached hereto as Appendix I, in such nominee name(s) as designated by the Purchaser, and bearing an appropriate legend referring to the fact that the Securities were
sold in reliance upon the exemption from registration under the Securities Act of 1933, as amended (the “Securities Act”), provided by Section 4(2) thereof and Rule 506 promulgated thereunder, (c) a true and complete copy of the
Company Disclosure Schedules, (d) evidence reasonably satisfactory to the Purchaser that the Company has received or will receive on the Closing Date at least $9,000,000 and not more than $24,000,000 in gross proceeds from the sale of Units
pursuant to this Agreement and the Other Agreements, (e) a certificate, dated as of the Closing Date, of the Secretary of the Company, and attested by another executive officer of the Company, certifying as to (i) the Certificate of
Incorporation and Bylaws of the Company, (ii) the resolutions adopted by the Company’s Board of Directors approving this Agreement and the other Transaction Documents and (iii) the signatures and authority of persons signing the
Transaction Documents on behalf of the Company and (f) an opinion of Vinson & Elkins L.L.P., counsel to the Company, in the form of Exhibit C hereto. In accordance with Section 4.38 hereof, the Company will promptly substitute one
or more replacement certificates without the legend upon (i) delivery by the Purchaser of the Purchaser’s Certificate of Subsequent Sale attached hereto as Appendix III and the legended certificate(s) at such time as the registration
statement to be filed by the Company pursuant to SECTION 7.1 hereof (the “Registration Statement”) is declared effective or (ii) Rule 144(k) under the Securities Act becoming available with respect to the Shares and submission of
legended certificate(s) to the Company’s transfer agent together with a representation letter in customary form. The name(s) in which the stock certificates and Warrant Certificates are to be registered are set forth in the Securities
Certificate Questionnaire attached hereto as Appendix I. 
  

 2 

 SECTION 4. Representations, Warranties and Covenants of the Company. The Company hereby
represents and warrants to, and, as applicable, covenants with, the Purchaser as follows (such representations and warranties being made as of the Closing Date unless otherwise expressly stated herein): 
  
 4.1 Organization and Qualification. The Company is a corporation
duly incorporated, validly existing and in good standing under the laws of the State of Delaware and the Company is qualified to do business as a foreign corporation in each jurisdiction in which qualification is required, except where failure to so
qualify would not reasonably be expected to have a Material Adverse Effect (as defined herein). All Subsidiaries (as defined herein) of the Company are listed on Exhibit B. Each Subsidiary is a direct or indirect wholly-owned subsidiary of the
Company. Each Subsidiary is duly organized, validly existing and in good standing under the laws of its jurisdiction of organization and is qualified to do business as a foreign entity in each jurisdiction in which qualification is required, except
where failure to so qualify would not reasonably be expected to have a Material Adverse Effect. For purposes of this Agreement, the term “Material Adverse Effect” shall mean (a) a material adverse effect upon the business, assets,
condition (financial or other), properties, results of operations or prospects of the Company and its Subsidiaries, taken as a whole, (b) any material adverse effect on the enforceability of the Agreement or the other Transaction Documents, or
(c) a material adverse effect on the ability of the Company to perform its obligations hereunder and under the other Transaction Documents. For purposes of this Agreement, the term “Subsidiary” means a “Significant
Subsidiary” as such term is defined in Regulation S-X promulgated under the Securities Act. 
  
 4.2 Authorized Capital Stock. As of October 20, 2005, the Company had authorized and issued and outstanding capital stock and shares reserved
for issuance pursuant to Company stock option plans and equity incentive programs as set forth in Section 4.2 of the Company Disclosure Schedule. The issued and outstanding shares of the Company’s Common Stock have been duly
authorized and validly issued, are fully paid and nonassessable, were issued in material compliance with applicable state and federal securities law and were not issued in violation of or subject to any preemptive rights or other rights to subscribe
for or purchase securities. Except as disclosed in Section 4.2 of the Company Disclosure Schedule, the Company does not have outstanding any options to purchase, or any preemptive rights or other rights to subscribe for or to purchase,
any securities or obligations convertible into, or any contracts or commitments to issue or sell, shares of its capital stock or any such options, rights, convertible securities or obligations. The description of the Company’s stock, stock
bonus and other stock plans or arrangements and the options or other rights granted and exercised thereunder set forth in Section 4.2 of the Company Disclosure Schedule accurately and fairly presents all material information with respect
to such plans, arrangements, options and rights. With respect to each Subsidiary, (a) all the issued and outstanding shares of each Subsidiary’s capital stock have been duly authorized and validly issued, are fully paid and nonassessable,
were issued in material compliance with applicable state and federal securities law and were not issued in violation of or subject to any preemptive rights or other rights to subscribe for or purchase securities, and (b) there are no
outstanding options to purchase, or any preemptive 
  

 3 

 rights or other rights to subscribe for or to purchase, any securities or obligations convertible into, or any contracts
or commitments to issue or sell, shares of the Subsidiary’s capital stock or any such options, rights, convertible securities or obligations. Except as described on Schedule 4.2 of the Company Disclosure Schedule, the issuance and sale
of the Securities hereunder will not obligate the Company to issue shares of Common Stock or other securities to any other Person (other than the Purchasers) and will not result in the adjustment of the exercise, conversion, exchange or reset price
of any outstanding security. Except as described in the Exchange Act Filings, the Company does not have outstanding stockholder purchase rights or “poison pill” or any similar arrangement in effect giving any Person the right to purchase
any equity interest in the Company upon the occurrence of certain events. As used herein, “Person” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization and
a government or any department or agency thereof. 
  
 4.3
Issuance, Sale and Delivery of the Securities. The Shares and the Warrant Shares have been duly authorized and, when issued, delivered and paid for in the manner set forth in the Transaction Documents, will be duly authorized, validly issued,
fully paid (assuming, in the case of the Warrant Shares, payment of the exercise price of the Warrants) and nonassessable and free and clear of all pledges, liens, restrictions and encumbrances (other than restrictions on transfer under state and/or
federal securities laws). The Company has a sufficient number of authorized but unissued shares of Common Stock reserved for issuance upon exercise of the Warrants. No preemptive rights or other rights to subscribe for or purchase exist with respect
to the issuance and sale of the Securities by the Company pursuant to this Agreement. No stockholder of the Company has any right (which has not been waived or has not expired by reason of lapse of time) following notification of the Company’s
intent to file the Registration Statement to require the Company to register the sale of any shares owned by such stockholder under the Securities Act in the Registration Statement. At the Closing, no further approval or authority of the
stockholders or the Board of Directors of the Company will be required for the issuance and sale of the Securities to be sold by the Company as contemplated herein. Assuming the accuracy of the Purchaser’s response under Section 2 of the
Registration Statement Questionnaire attached as Appendix II hereto, and without taking into account any future purchases of Shares (other than Warrant Shares) (a) the issuance and sale of the Securities, (b) the issuance of the Warrant
Shares upon due exercise of the Warrants, and (c) the other transactions contemplated by the Transaction Documents (including without limitation the ownership, disposition or voting of the Securities by the Purchasers or the exercise of any
right granted to the Purchasers pursuant to this Agreement or the other Transaction Documents) (i) will not give any Person the right to purchase any equity interest in the Company under the provisions of any stockholder rights plan or other
“poison pill” arrangement, and (ii) are not prohibited by any anti-takeover, business combination or control share law or statute binding on the Company or to which the Company or any of its assets and properties may be subject or any
provision of the Company’s Certificate of Incorporation or Bylaws. 
  
 4.4 Due Execution, Delivery and Performance of the Transaction Documents. The Company has full corporate power and authority to enter into the Transaction Documents and perform the transactions contemplated
thereby. Each of the Transaction Documents has been duly authorized, executed and delivered by the Company. The execution, delivery and performance of the Transaction Documents by the Company and the consummation of the transactions contemplated
thereby do not and will not violate any provision of the 
  

 4 

 certificate of incorporation or bylaws of the Company or any of its Subsidiaries and will not result in the creation of
any lien, charge, security interest or encumbrance upon any assets of the Company or any of its Subsidiaries pursuant to the terms or provisions of, and will not conflict with, result in the breach or violation of, or constitute, either by itself or
upon notice or the passage of time or both, a default under (a) any agreement, lease, franchise, license, permit or other instrument to which the Company or any of its Subsidiaries is a party or by which the Company or any of its Subsidiaries
or any of their respective properties may be bound or affected and in each case which would reasonably be expected to have a Material Adverse Effect, or (b) any statute or any judgment, decree, order, rule or regulation of any court or any
regulatory body, administrative agency or other governmental body applicable to the Company or any of its Subsidiaries or any of their respective properties where such conflict, breach, violation or default would reasonably be expected to have a
Material Adverse Effect. No consent, approval, authorization or other order of any court, regulatory body, administrative agency or other governmental body is required for the execution and delivery of the Transaction Documents or the consummation
of the transactions contemplated thereby, except for compliance with the blue sky laws and federal securities laws applicable to the offering of the Securities. Upon the execution and delivery by the Company of the Transaction Documents, and
assuming the valid execution of this Agreement by the Purchaser, each Transaction Document to which the Purchaser is a party will constitute a valid and binding obligation of the Company, enforceable in accordance with its terms, except as
enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ and contracting parties’ rights generally and except as enforceability may be subject to general principles
of equity (regardless of whether such enforceability is considered in a proceeding in equity or at law) and except as the indemnification agreements of the Company in SECTION 7.3 hereof may be limited by federal or state securities laws or the
public policy underlying such laws. 
  
 4.5 Accountants.
To the Company’s knowledge, the firm of KPMG LLP, which has expressed its opinion with respect to the consolidated financial statements of the Company included in the Company’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2004 and to be included or incorporated by reference in the Registration Statement and the prospectus which forms a part thereof (the “Prospectus”), is an independent accountant as required by the Securities Act and the
rules and regulations promulgated thereunder (the “Rules and Regulations”). As used in this Agreement, the Company’s knowledge means the actual knowledge of the executive officers of the Company (as such term is defined in Rule 405
under the Securities Act), and the knowledge they would reasonably be expected to obtain after due inquiry. 
  
 4.6 No Defaults. Except as disclosed in Section 4.6 of the Company Disclosure Schedule, neither the Company nor any of its
Subsidiaries is in violation or default of any provision of its certificate of incorporation or bylaws, or in breach of or default with respect to any provision of any agreement, judgment, decree, order, lease, franchise, license, permit or other
instrument to which it is a party or by which it or any of its properties are bound which would reasonably be expected to have a Material Adverse Effect and no event has occurred which, with notice or lapse of time or both, would constitute an event
of default on the part of the Company or any of its Subsidiaries as defined in such documents and which would reasonably be expected to have a Material Adverse Effect. 
  

 5 

 4.7 Contracts. The documents filed with or incorporated by reference in the Company’s Annual
Report on Form 10-K for the fiscal year ended December 31, 2004, and the Exchange Act Filings filed with the Commission after such Annual Report on Form 10-K through the date hereof comprise all of the agreements to which the Company or any
Subsidiary of the Company is subject (other than any Transaction Documents) that are of a type that would be required to be included as an exhibit to a Registration Statement on Form S-1 pursuant to the Rules and Regulations if such a registration
statement were filed by the Company on the date hereof. Except as would not reasonably be expected to have a Material Adverse Effect, neither the Company nor any Subsidiary of the Company is in breach or default under any agreement to which the
Company or any Subsidiaries of the Company is subject nor, to the Company’s knowledge, is any other party to any such agreement in breach or default thereunder. 
  
 4.8 No Actions. Except as disclosed in Section 4.8 of the Company Disclosure Schedule, (a) there
are no legal or governmental actions, suits or proceedings pending and (b) to the Company’s knowledge, there are no inquiries or investigations, nor are there any legal or governmental actions, suits, or proceedings threatened, in each
case, to which the Company or any of its Subsidiaries is or may be a party or of which property owned or leased by the Company or any of its Subsidiaries is or may be the subject, or related to environmental or discrimination matters, which actions,
suits or proceedings, individually or in the aggregate, would reasonably be expected to have a Material Adverse Effect; and no labor disturbance by the employees of the Company exists or, to the Company’s knowledge, is imminent which would
reasonably be expected to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries is party to or subject to the provisions of any injunction, judgment, decree or order of any court, regulatory body, administrative agency or
other governmental body. 
  
 4.9 Properties. The Company
and its Subsidiaries have good and defensible title to all properties and assets reflected as owned by them in the financial statements included in the Exchange Act Filings, subject to no lien, mortgage, pledge, charge or encumbrance of any kind
except (a) those, if any, reflected in the financial statements included in the Exchange Act Filings or Section 4.9 of the Company Disclosure Schedule, or (b) those that are not material in amount and do not adversely affect
the use of such property by the Company and its Subsidiaries. Each of the Company and its Subsidiaries holds its leased properties under valid and binding leases, with such exceptions as are not materially significant in relation to its business
taken as a whole. Except as disclosed in Section 4.9 of the Company Disclosure Schedule, the Company has good and defensible title in fee simple to, or has valid rights to lease or otherwise use, all items of real or personal property
currently being used in the business of the Company that are necessary to its operations as now conducted. 
  
 4.10 No Material Change. Since June 30, 2005 and except as described in Section 4.10 of the Company Disclosure Schedule,
(a) the Company and its Subsidiaries have not incurred any material liabilities or obligations, indirect or contingent, or entered into any material oral or written agreement or other transaction, in each case, which is not in the ordinary
course of business or which would reasonably be expected to have a Material Adverse Effect; (b) the Company and its Subsidiaries have not sustained any loss or damage to its physical properties from fire, flood, windstorm, accident or other
calamity not covered by insurance which would reasonably be expected to have a Material Adverse Effect; (c) the Company and its Subsidiaries have not paid or declared any dividends or other distributions with respect to their 
  

 6 

 capital stock and neither the Company nor any of its Subsidiaries is in default in the payment of principal or interest
on any outstanding debt obligations; (d) there has not been any change in the capital stock of the Company or any of its Subsidiaries other than the sale of the Securities in the Offering, shares or options issued pursuant to employee equity
incentive plans or purchase plans approved by the Company’s Board of Directors and repurchases of shares or options pursuant to repurchase plans already approved by the Company’s Board of Directors; (e) the Company and its
Subsidiaries have not incurred any indebtedness outside the ordinary course of business that is material to the Company and its Subsidiaries, taken as a whole; and (f) there has not been any other event which has caused or is reasonably
expected to result in a Material Adverse Effect. 
  
 4.11
Intellectual Property. (a) Except as disclosed in Section 4.11 of the Company Disclosure Schedule, to the Company’s knowledge, the Company owns or has obtained valid and enforceable licenses or options for the material
inventions, patent applications, patents, trademarks (both registered and unregistered), trade names, copyrights and trade secrets necessary for the conduct of the Company’s business as currently conducted (collectively, the “Intellectual
Property”); and (b) (i) there are no third parties who have any ownership rights to any Intellectual Property that is owned by, or has been licensed to, the Company for the products except as described in Section 4.11 of the
Company Disclosure Schedule that would preclude the Company from conducting its business as currently conducted and have a Material Adverse Effect, except for the ownership rights of the owners of the Intellectual Property licensed or optioned
by the Company; (ii) to the Company’s knowledge, there are currently no sales of any products that would constitute an infringement by third parties of any Intellectual Property owned, licensed or optioned by the Company; (iii) there
is no pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others challenging the rights of the Company in or to any Intellectual Property owned, licensed or optioned by the Company; (iv) there is no
pending or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any Intellectual Property owned, licensed or optioned by the Company; and (v) there is no pending or, to
the Company’s knowledge, threatened action, suit, proceeding or claim by others that the Company infringes or otherwise violates any patent, trademark, copyright, trade secret or other proprietary right of others. 
  
 4.12 Compliance. Neither the Company nor any of its Subsidiaries has
been advised, nor has reason to believe, that it is not conducting its business in compliance with all applicable laws, rules and regulations of the jurisdictions in which it is conducting its business, including, without limitation, all applicable
local, state and federal environmental laws and regulations, except where failure to be so in compliance would not reasonably be expected to have a Material Adverse Effect. 
  
 4.13 Taxes. Except as set forth in Section 4.13 of the Company Disclosure Schedule, each of the Company
and its Subsidiaries has filed all material federal, state and foreign income and franchise tax returns that it was required to file or has obtained an extension of time within which to file such tax returns as allowed by applicable law. Each of the
Company and its Subsidiaries has paid or accrued all taxes shown as due on such returns or extensions for payment have been properly obtained or such taxes are being timely and properly contested, and neither the Company nor any of its Subsidiaries
has knowledge of a tax deficiency which has been or might be asserted or threatened against it which would reasonably be expected to have a Material Adverse Effect. 
  

 7 

 4.14 Transfer Taxes. On the Closing Date, all stock transfer or other taxes (other than income or
similar taxes) which are required to be paid in connection with the sale and transfer of the Securities to be sold to the Purchaser hereunder will be, or will have been, fully paid or provided for by the Company and all laws imposing such taxes will
be or will have been complied with. 
  
 4.15 Investment
Company. The Company is not an “investment company” or an “affiliated person” of, or “promoter” or “principal underwriter” for, an investment company, within the meaning of the Investment Company Act of
1940, as amended. 
  
 4.16 Offering Materials. The Company
has not distributed any offering material in connection with the Offering. Except for the registration and sale of the securities as contemplated by SECTION 7 of this Agreement, neither the Company nor any person acting on its behalf has in the past
or will hereafter take any action independent of the Placement Agent to sell, offer for sale or solicit offers to buy any securities of the Company which would subject the offer, issuance or sale of the Securities, as contemplated by this Agreement,
to the registration requirements of Section 5 of the Securities Act. 
  
 4.17 Insurance. The Company and its Subsidiaries maintain insurance of the types and in the amounts that the Company reasonably believes is adequate for their businesses (taking into account the cost and
availability of such insurance), including, but not limited to, insurance covering all real and personal property leased by the Company and its Subsidiaries against theft, damage, destruction, acts of vandalism and all other risks customarily
insured against by similarly situated companies, all of which insurance is in full force and effect as of the date of this Agreement. 
  
 4.18 Additional Information. The information contained in the following documents (the “Exchange Act Filings”) did not, as of the filing
date of the applicable document or the date of the draft Registration Statement (which the Placement Agent has furnished to the Purchaser), as applicable, include any untrue statement of a material fact or omit to state any material fact required to
be stated therein or necessary to make the statements therein (except for the draft Registration Statement, in the light of the circumstances in which they were made) not misleading, as of their respective filing dates or the date of the draft
Registration Statement, as applicable: 
  
 (a) the
Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2004; 
  
 (b) the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2005; 
  
 (c) the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “Commission”) on April 11, 2005,
regarding a change in the Company’s independent public accountants; 
  

 8 

 (d) the Company’s Current Report on Form 8-K filed with the Commission on May 16, 2005,
regarding an amendment to the Company’s Employee Stock Purchase Plan; 
  
 (e) the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2005; 
  
 (f) the Company’s definitive Proxy Statement, as supplemented, for its Annual Meeting of Stockholders held on May 10, 2005; 
  
 (g) the draft Registration Statement; and 
  
 (h) all other documents, if any, filed by the Company with the Commission
since December 31, 2004 through the Closing Date pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). 
  
 4.19 Price of Common Stock. The Company has not taken, and will not take, directly or indirectly, any action
prohibited by Regulation M as promulgated under the Exchange Act that is intended to stabilize or manipulate the price of the shares of the Common Stock to facilitate the sale or resale of the Securities. 
  
 4.20 Corporate Legal Opinion. At the Closing, Vinson &
Elkins L.L.P., legal counsel to the Company, will deliver a legal opinion to the Purchasers in the form substantially as set forth in Exhibit C hereto. 
  
 4.21 [reserved] 
  
 4.22 Reporting Company; Form S-3. The Company is subject to the reporting requirements of the Exchange Act and has filed all reports required to
be filed by the Company pursuant to the Exchange Act for a period of at least 12 calendar months immediately preceding the date hereof. The Company is eligible to register the Shares and the Warrant Shares for resale by the Purchaser on a
registration statement on Form S-3 under the Securities Act. To the Company’s knowledge, there exist no facts or circumstances (including without limitation any required approvals or waivers or any circumstances that may delay or prevent the
obtaining of accountant’s consents) that reasonably could be expected to prohibit or delay the preparation and filing of a registration statement on Form S-3 that will be available for the resale of the Shares or the Warrant Shares by the
Purchaser. 
  
 4.23 Use of Purchaser Name. Except as may
be required by applicable law or regulation, the Company shall not use the Purchaser’s name or the name of any of its affiliates in any advertisement, announcement, press release or other similar public communication unless it has received the
prior written consent of the Purchaser for the specific use contemplated or as otherwise required by applicable law or regulation. 
  
 4.24 Related Party Transactions. Except as disclosed in the Exchange Act Filings, none of the officers or directors of the Company and, to the
Company’s knowledge, none of the employees of the Company is currently a party to any transaction with the Company or any Subsidiary (other than as holders of stock options and/or warrants, and for services as 
  

 9 

 employees, officers and directors or pursuant to indemnification agreements), including any contract, agreement or other
arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the Company’s knowledge, any
entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner. 
  
 4.25 Off-Balance Sheet Arrangements. There is no transaction, arrangement or other relationship between the Company and an unconsolidated or other
off-balance sheet entity that is required to be disclosed by the Company in its Exchange Act Filings and is not so disclosed. There are no such transactions, arrangements or other relationships with the Company that may create contingencies or
liabilities that are not otherwise disclosed by the Company in its Exchange Act Filings. 
  
 4.26 Governmental Permits, Etc. Each of the Company and its Subsidiaries has all franchises, licenses, certificates and other authorizations from such federal, state or local government or governmental agency,
department or body that are currently required for the operation of the business of the Company and its Subsidiaries as currently conducted, except where the failure to possess currently such franchises, licenses, certificates and other
authorizations would not reasonably be expected to have a Material Adverse Effect. The Company and its Subsidiaries have not received any notice of proceedings relating to the revocation or modification of any such permit which, if the subject of an
unfavorable decision, ruling or finding, would reasonably be expected to have a Material Adverse Effect. 
  
 4.27 Financial Statements. The consolidated financial statements of the Company and the related notes contained in its Exchange Act Filings
present fairly in all material respects, in accordance with generally accepted accounting principles, the consolidated financial position of the Company and its Subsidiaries as of the dates indicated, and the results of their operations, cash flows
and the changes in stockholders’ equity for the periods therein specified, subject, in the case of unaudited financial statements for interim periods, to normal year-end audit adjustments and the absence of full footnote disclosure as required
by generally accepted accounting principles. Such consolidated financial statements (including the related notes) have been prepared in accordance with generally accepted accounting principles applied on a consistent basis throughout the periods
therein specified, subject, in the case of unaudited financial statements for interim periods, to normal year-end adjustments, and except as otherwise described therein and except that unaudited financial statements may not contain all footnotes
required by generally accepted accounting principles. 
  
 4.28
Sarbanes-Oxley Act. Except as described in the Exchange Act Filings, the Company is in material compliance with the provisions of the Sarbanes-Oxley Act of 2002 currently applicable to the Company. Except as described in the Exchange Act
Filings, the Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations,
(ii) transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability, (iii) access to assets is permitted only in
accordance with management’s general or specific authorization, and (iv) the recorded 
  

 10 

 accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken
with respect to any differences. Except as described in the Exchange Act Filings, the Company has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-14 and 15d-14) for the Company and designed such disclosure
controls and procedures to ensure that material information relating to the Company, including the Subsidiaries, is made known to the certifying officers by others within those entities, particularly during the period in which the Company’s
most recently filed period report under the Exchange Act, as the case may be, is being prepared. The Company’s certifying officers have evaluated the effectiveness of the Company’s controls and procedures as of the end of the period
covered by the most recently filed periodic report under the Exchange Act (such date, the “Evaluation Date”). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the certifying
officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no significant changes in the Company’s internal controls (as such term
is defined in Item 308 of Regulation S-K) or, to the Company’s knowledge, in other factors that could significantly affect the Company’s internal controls. Except as described in the Exchange Act Filings, the Company maintains a
standard system of accounting established and administered in accordance with generally accepted accounting principles and the applicable requirements of the Exchange Act. 
  
 4.29 Listing. The Company shall comply with all requirements of the Nasdaq National Market with respect to the
issuance of the Shares and the Warrant Shares. The Company is in compliance in all material respects with applicable Nasdaq National Market System continued listing requirements and has not, in the two years preceding the date hereof, received any
notice (written or oral) from the Nasdaq National Market, any stock exchange, market or trading facility on which the Common Stock is or has been listed (or on which it has been quoted) to the effect that the Company is not in compliance in all
material respects with the listing or maintenance requirements of such exchange, market or trading facility. The Company shall comply with all requirements of the Nasdaq National Market with respect to the issuance of Shares and the Warrant Shares
and shall use its commercially reasonable efforts to have the Shares and the Warrant Shares listed on the Nasdaq National Market as promptly as practicable following the Closing. 
  
 4.30 Foreign Corrupt Practices. Neither the Company, nor any of its Subsidiaries, nor, to the knowledge of the
Company, any director, officer, agent, employee or other Person acting on behalf of the Company or any of its Subsidiaries has, in the course of its actions for, or on behalf of, the Company (i) used any corporate funds for any unlawful
contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii) made any direct or indirect unlawful payment to any foreign or domestic government official or employee from corporate funds; (iii) violated
or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended; or (iv) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any foreign or domestic government
official or employee. 
  
 4.31 Employee Relations. Neither
the Company nor any of its Subsidiaries is a party to any collective bargaining agreement, and no union or other labor organization represents any employees of the Company or any of its Subsidiaries. The 
  

 11 

 Company and its Subsidiaries believe that their relations with their employees are good. No executive officer of the
Company (as defined in Rule 501(f) of the Securities Act) has notified the Company that such officer intends to leave the Company or otherwise terminate such officer’s employment with the Company. No executive officer of the Company, to the
knowledge of the Company, is, or is now expected to be, in violation in any material respect of any employment contract, confidentiality, disclosure or proprietary information agreement, non-competition agreement, or other contract or agreement or
restrictive covenant. 
  
 4.32 ERISA. To the knowledge of
the Company, at all times within the three years prior to the date of this Agreement: (a) the Company has been in compliance, in all material respects, with all presently applicable provisions of the Employee Retirement Income Security Act of
1974, as amended, including the regulations and published interpretations thereunder (“ERISA”), except as would not reasonably be expected to have a Material Adverse Effect; (b) no “reportable event” (as defined in ERISA)
has occurred with respect to any “pension plan” (as defined in ERISA) for which the Company would have any liability; (c) the Company has not incurred and does not expect to incur liability under (i) Title (IV) of ERISA with
respect to termination of, or withdrawal from, any “pension plan” or (ii) Sections 412 or 4917 of the Internal Revenue Code of 1986, as amended, including the regulations and published interpretations thereunder (the
“Code”); and (d) each “pension plan” for which the Company would have any liability that is intended to be qualified under Section 401(a) of the Code is so qualified in all material respects and nothing has occurred,
whether by action or by failure to act, which, in each case, would cause the loss of such qualification, except as would not reasonably be expected to have a Material Adverse Effect. 
  
 4.33 Environmental Matters. There has been no storage, disposal, generation, manufacture, transportation, handling
or treatment of toxic wastes, hazardous wastes or hazardous substances by the Company or to its knowledge, any of its Subsidiaries (or, to the knowledge of the Company, any of their predecessors in interest) at, upon or from any of the property now
or previously owned or leased by the Company or any of its Subsidiaries in violation of any applicable law, ordinance, rule, regulation, order, judgment, decree or permit or which would require remedial action under any applicable law, ordinance,
rule, regulation, order, judgment, decree or permit, except for such violations as would not reasonably be expected to result in a Material Adverse Effect; there has been no spill, discharge, leak, emission, injection, escape, dumping or release of
any kind into such property or into the environment surrounding such property of any toxic wastes, medical wastes, solid wastes, hazardous wastes or hazardous substances due to or caused by the Company or any of its Subsidiaries or with respect to
which the Company has knowledge which, individually or in the aggregate, would have a Material Adverse Effect; the terms “hazardous wastes”, “toxic wastes”, “hazardous substances”, and “medical wastes” shall
have the meanings specified in any applicable local, state, federal and foreign laws or regulations with respect to environmental protection. 
  
 4.34 Brokers and Finders. No Person will have, as a result of the transactions contemplated by the Transaction Documents, any valid right,
interest or claim against or upon the Company, any Subsidiary or the Purchaser for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company, other than as described
in Section 4.34 of the Company Disclosure Schedule. 
  

 12 

 4.35 No Directed Selling Efforts or General Solicitation. Neither the Company nor any Person
acting on its behalf has conducted any general solicitation or general advertising (as those terms are used in Regulation D) in connection with the offer or sale of any of the Securities. 
  
 4.36 Private Placement. The offer and sale of the Securities to the Purchasers as contemplated by the Transaction
Documents is exempt from the registration requirements of the Securities Act. 
  
 4.37 Disclosures. The Company hereby agrees that it will publicly disclose the Non-Public Information (as defined below) no later than 5:00 p.m., New York time on October 27, 2005 (the “Disclosure
Deadline”). The Company further agrees that it will not provide to the Purchaser any material, non-public information regarding the Company that it does not intend to publicly disclose on or prior to the Disclosure Deadline. The Company
acknowledges that the Purchaser will be relying on this representation in effecting transactions in the Company’s securities. 
  
 4.38 Removal of Legends. Upon the earlier of (i) the disposition of the Securities and the receipt by the Company of a Certificate of
Subsequent Sale in the form of Appendix III hereof at such time as the Registration Statement is effective or (ii) Rule 144(k) under the Securities Act becoming available with respect to the Securities, the Company shall, upon the
Purchaser’s written request, promptly cause certificates evidencing the Purchaser’s Securities to be replaced with certificates which do not bear such restrictive legends, and Warrant Shares subsequently issued upon due exercise of the
Warrants shall not bear such restrictive legends provided the provisions of either clause (i) or clause (ii) above, as applicable, are satisfied with respect to such Warrant Shares. When the Company is required to cause unlegended
certificates to replace previously issued legended certificates, if unlegended certificates are not delivered to the Purchaser within three (3) Business Days of submission by the Purchaser of legended certificate(s) to the Company’s
transfer agent together with a representation letter in customary form (with copies thereof submitted to the Company), the Company shall be liable to the Purchaser for liquidated damages in an amount equal to 1.0% of the aggregate purchase price of
the Securities evidenced by such certificate(s) for each thirty (30) day period (or pro rata for any period of less than thirty (30) days) beyond such three (3) Business Days that the unlegended certificates have not been so
delivered. 
  
 SECTION 5. Representations, Warranties and
Covenants of the Purchaser. (a) The Purchaser represents and warrants to, and covenants with, the Company that: (i) the Purchaser is knowledgeable, sophisticated and experienced in making, and is qualified to make, decisions with respect to
investments in securities representing an investment decision like that involved in the purchase of the Securities, including investments in securities issued by the Company and comparable entities, and has requested, received, reviewed and
considered all information it deems relevant in making an informed decision to purchase the Securities; (ii) the Purchaser is acquiring the Securities set forth in SECTION 2 above in the ordinary course of its business and for its own account for
investment only and with no present intention or view to the 
  

 13 

 public sale or distribution of any of such Securities, and no arrangement or understanding exists with any other persons
regarding the public sale or distribution of such Securities without prejudice, however, to such Purchaser’s right at all times to sell or otherwise dispose of all or any part of such Securities in compliance with applicable federal and state
securities laws; and provided, however, that nothing contained herein shall be deemed a representation or warranty by such Purchaser to hold the Securities for any period of time; (iii) the Purchaser will not, directly or indirectly, offer,
sell, pledge, transfer or otherwise dispose of (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of) any of the Securities, nor will the Purchaser engage in any short sale that results in a disposition of any of the
Securities by the Purchaser, except in compliance with the Securities Act and the Rules and Regulations and any applicable state securities laws; (iv) since the time it became aware of the Offering, the Purchaser and its affiliates have not
entered into, any “put equivalent position” as such term is defined in Rule 16a-1 under the Exchange Act or short sale positions with respect to the Common Stock; (v) the Purchaser has completed or caused to be completed the
Registration Statement Questionnaire attached hereto as Appendix II, for use in preparation of the Registration Statement; (vi) the Purchaser has, in connection with its decision to purchase the Securities set forth in SECTION 2 above, not
relied on any information provided by the Company other than the Exchange Act Filings and the representations and warranties of the Company contained herein; (vii) the Purchaser has had an opportunity to discuss this investment with
representatives of the Company and ask questions of them (although the Purchaser and the Company each acknowledges that neither such discussions nor any other due diligence investigation conducted by the Purchaser or any of its advisors or
representatives modifies, amends or affects the Company’s representations and warranties contained in SECTION 4 hereof or limits the ability of the Purchaser to rely thereon); and (viii) the Purchaser is an “accredited investor”
within the meaning of Rule 501(a) of Regulation D promulgated under the Securities Act. 
  
 (b) The Purchaser understands that the Securities are being offered and sold to it in reliance upon specific exemptions from the registration requirements of the Securities Act, the Rules and Regulations and state
securities laws and that the Company is relying upon the truth and accuracy of, and the Purchaser’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Purchaser set forth herein in order to
determine the availability of such exemptions and the eligibility of the Purchaser to acquire the Securities. 
  
 (c) The Purchaser acknowledges that it has received from the Company certain non-public information regarding the Company (the “Non-Public
Information”), and the Purchaser acknowledges that applicable United States securities laws may prohibit the Purchaser from purchasing or selling securities of the Company on the basis of such Non-Public Information or from communicating such
Non-Public Information to any other Person under circumstances in which it is reasonably foreseeable that such Person is likely to purchase or sell such securities. Accordingly, the Purchaser agrees that, until the Non-Public Information is absorbed
by the marketplace after the Disclosure Deadline, the Purchaser shall not purchase or sell securities of the Company or communicate any Non-Public Information to any other Person under circumstances in which it is reasonably foreseeable that such
Person is likely to purchase or sell such securities. 
  

 14 

 (d) The Purchaser understands that its investment in the Securities involves a significant degree of
risk, including a risk of total loss of the Purchaser’s investment, and the Purchaser has full cognizance of and understands all of the risk factors related to the Purchaser’s purchase of the Securities, including, but not limited to,
those set forth under the caption “Risk Factors” in the draft Registration Statement. The Purchaser understands that the market price of the Common Stock has been volatile and that no representation is being made as to the future value of
the Common Stock. The Purchaser has the knowledge and experience in financial and business matters as to be capable of evaluating the merits and risks of an investment in the Securities and has the ability to bear the economic risks of an investment
in the Securities. 
  
 (e) The Purchaser understands that no
United States federal or state agency or any other government or governmental agency has passed upon or made any recommendation or endorsement of the Securities. 
  
 (f) The Purchaser understands that, until such time as the Registration Statement has become effective or until such time
as the Shares, the Warrants or the Warrant Shares may be sold pursuant to Rule 144(k) under the Securities Act, such securities will bear a restrictive legend in substantially the following form: 
  
 “The securities evidenced by this certificate have not been registered
under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state or other jurisdiction. The securities may not be offered, sold, pledged or otherwise transferred except (1) pursuant to an
exemption from registration under the Securities Act or (2) pursuant to an effective registration statement under the Securities Act, in each case in accordance with all applicable securities laws of the states and other jurisdictions, and in
the case of a transaction exempt from registration), unless the Company has received an opinion of counsel reasonably satisfactory to it that such transaction does not require registration under the Securities Act and such other applicable
laws.” 
  
 (g) The Purchaser’s principal executive
offices are in the jurisdiction set forth immediately below the Purchaser’s signature on the signature pages hereto. 
  
 (h) The Purchaser hereby covenants with the Company not to make any sale of the Securities without complying with applicable securities laws. The
Purchaser further agrees not to make any sale of the Shares or the Warrant Shares pursuant to the Registration Statement without effectively causing the prospectus delivery requirement under the Securities Act to be satisfied at a time when the
Company has notified the Purchaser that the conditions specified in Rule 172(c)(1) or Rule 172(c)(2) under the Securities Act are not satisfied. The Purchaser also agrees that the Shares and Warrant Shares are not transferable on the books of the
Company (other than transfers pursuant to Rule 144 under the Securities Act) unless the certificate submitted to the transfer agent evidencing the Shares or the Warrant Shares 
  

 15 

 is accompanied by a separate Purchaser’s Certificate of Subsequent Sale in the form of Appendix III hereto that is
executed by an officer of, or other authorized person designated by, the Purchaser. The Purchaser acknowledges that there may occasionally be times when the Company must suspend the use of the prospectus forming a part of the Registration Statement
(a “Suspension”) until such time as an amendment to the Registration Statement has been filed by the Company and declared effective by the Commission, or such time as each prospectus has been supplemented, or until such time as the Company
has filed an appropriate report with the Commission pursuant to the Exchange Act. Subject to the Purchaser’s right to receive liquidated damages under the circumstances described in Section 7.1(b), the Purchaser hereby covenants that it
will use its best efforts not to sell any Shares or any Warrant Shares pursuant to said prospectus during the period commencing at the time at which the Company gives the Purchaser written notice of the Suspension of the use of said prospectus and
ending at the time the Company gives the Purchaser written notice that the Purchaser may thereafter effect sales pursuant to said prospectus. Notwithstanding the foregoing, no Suspension shall exceed 45 consecutive days or an aggregate of 70 days in
any 365-day period. 
  
 (i) The Purchaser further represents and
warrants to, and covenants with, the Company that (i) the Purchaser has full right, power, authority and capacity to enter into the Transaction Documents and to consummate the transactions contemplated therein and has taken all necessary action
to authorize the execution, delivery and performance of the Transaction Documents, (ii) the making and performance of the Transaction Documents by the Purchaser and the consummation of the transactions contemplated therein will not conflict
with or result in a breach or violation of any provision of the organizational documents of the Purchaser or conflict with, result in the breach or violation of, or constitute, either by itself or upon notice or the passage of time or both, a
default under any material agreement, mortgage, deed of trust, lease, franchise, license, indenture, permit or other instrument to which the Purchaser is a party, or any statute or any authorization, judgment, decree, order, rule or regulation of
any court or any regulatory body, administrative agency or other governmental body applicable to the Purchaser, (iii) no consent, approval, authorization or other order of any court, regulatory body, administrative agency or other governmental
body is required on the part of the Purchaser for the execution and delivery of the Transaction Documents or the consummation of the transactions contemplated therein, (iv) upon the execution and delivery of the Transaction Documents, each
Transaction Document shall constitute a legal, valid and binding obligation of the Purchaser, enforceable in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or
similar laws affecting creditors’ and contracting parties’ rights generally and except as enforceability may be subject to general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or
at law) and except to the extent enforcement of the indemnification provisions, set forth in SECTION 7.3 of this Agreement, may be limited by federal or state securities laws or the public policy underlying such laws, (v) there is not in effect
any order enjoining or restraining the Purchaser from entering into or engaging in any of the transactions contemplated by the Transaction Documents, (vi) the Purchaser has no present intent to change or influence the control of the Company
within the meaning of Rule 13d-1 of the Exchange Act, and (vii) the Purchaser understands that nothing in this Agreement or any other materials provided to the Purchaser in connection with the purchase and sale of the Securities constitutes
legal, tax or investment advice. The Purchaser has consulted its own legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate in connection with the purchase of the Securities. 
  

 16 

 SECTION 6. Survival of Representations and Warranties. Notwithstanding any investigation made by
any party to this Agreement or by the Placement Agent, all representations and warranties made by the Company and the Purchaser herein and in the certificates for the Securities delivered pursuant hereto shall survive the execution of this
Agreement, the delivery to the Purchaser of the Shares and Warrants being purchased and the payment therefore for a period of twelve (12) months from the Closing Date. 
  
 SECTION 7. Registration of the Securities; Compliance with the Securities Act. 
  
 7.1 Registration Procedures and Expenses. The Company shall:

  
 (a) subject to receipt of necessary information from the
Purchaser, as promptly as practicable, but in no event later than fifteen days after the Closing Date (such date, a “Filing Date”) prepare and file with the Commission the Registration Statement, which shall be on Form S-3, relating to the
sale of the Shares and the Warrant Shares by the Purchaser and the Other Purchasers in accordance with the Plan of Distribution attached hereto as Appendix IV; 
  

(b) use its commercially reasonable efforts, subject to receipt of necessary information from the Purchaser, to cause the Commission to declare the
Registration Statement effective within sixty (60) calendar days after the Filing Date (such date, the “Required Effective Date”); provided, however, that if the Company filed the Registration Statement by the Filing Date and the
Registration Statement receives Commission review, then the Required Effective Date will be the one hundred fifth (105th) calendar day after the Filing Date. If the Registration Statement is (A) not filed with the Commission on or before
the Filing Date or (B) not declared effective by the Commission on or before the earlier of (i) five Business Days after the Commission has advised the Company that no review will be made of the Registration Statement or that the
Commission has no further comments on the Registration Statement and (ii) the Required Effective Date, or (iii) following the initial effectiveness of the Registration Statement, the Registration Statement becomes unavailable for sales
thereunder other than as a result of a Suspension of less than 45 consecutive days or an aggregate of 70 days in any 365-day period (each, an “Event”), then, as relief for the damages to the Purchaser by reason of any such delay in or
reduction of its ability to sell the Shares or Warrant Shares (which remedy shall not be exclusive of any other non-monetary remedies available at law or in equity), the Company shall pay to the Purchaser, for every thirty (30) days that such
Event occurs and is continuing (or pro rata for any period of less than thirty (30) days), an amount in cash equal to: (i) the aggregate purchase price of such Purchaser’s Securities as reflected in SECTION 2 multiplied by
(ii) 0.01. The foregoing liquidated damages shall constitute the sole monetary remedy available to the Purchaser upon the occurrence of an Event. 
  
 (c) provide copies to and permit Lowenstein Sandler PC to review each Registration Statement and all amendments and supplements thereto no fewer than
three (3) days prior to their filing with the Commission and not file any document to which such counsel reasonably objects; 
  

 17 

 (d) furnish to the Purchaser and its legal counsel promptly after the same is prepared and publicly
distributed, filed with the Commission, or received by the Company (but not later than two (2) Business Days after the filing date, receipt date or sending date, as the case may be) one (1) copy of any Registration Statement and any
amendment thereto, each preliminary prospectus and Prospectus and each amendment or supplement thereto, and each letter written by or on behalf of the Company to the Commission or the staff of the Commission, and each item of correspondence from the
Commission or the staff of the Commission, in each case relating to such Registration Statement (other than any portion of any thereof which contains information for which the Company has sought confidential treatment); 
  
 (e) prior to any public offering of the Shares and the Warrant Shares, use
commercially reasonable efforts to register or qualify such Shares and Warrant Shares for offer and sale under the securities or blue sky laws of such jurisdictions requested by the Purchasers and do any and all other commercially reasonable acts or
things necessary or advisable to enable the distribution in such jurisdictions of the Shares and the Warrant Shares; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (i) qualify to
do business in any jurisdiction where it would not otherwise be required to qualify but for this clause (e), (ii) subject itself to general taxation in any jurisdiction where it would not otherwise be so subject but for this clause (e), or
(iii) file a general consent to service of process in any such jurisdiction; 
  
 (f) use its commercially reasonable efforts to promptly prepare and file with the Commission such amendments and supplements to the Registration Statement and the prospectus used in connection therewith as may be
necessary to keep the Registration Statement effective until the earlier of (i) the date on which the Shares and the Warrant Shares may be resold by the Purchasers without registration by reason of Rule 144(k) under the Securities Act; or
(ii) such time as all Shares and Warrant Shares purchased by such Purchaser under this Agreement have been sold. Thereafter, the Company shall be entitled to withdraw the Registration Statement and the Purchasers shall have no further right to
offer or sell any of the Shares or Warrant Shares pursuant to the Registration Statement; 
  
 (g) furnish to the Purchaser with respect to the Shares and the Warrant Shares registered under the Registration Statement (and to each underwriter, if any, of such Shares and Warrant Shares) such number of copies of
prospectuses and such other documents as the Purchaser may reasonably request, fulfill in all respects the condition specified in Rule 172(c)(3) under the Securities Act and notify the Purchaser when the conditions specified in Rule 172(c)(1) or
Rule 172(c)(2) under the Securities Act are not satisfied; 
  
 (h) notify the Purchaser on the day that the Registration Statement or any post-effective amendment thereto is declared effective; 
  
 (i) notify the Purchaser, at any time when a prospectus relating to the Shares or the Warrant Shares is required to be delivered under the Securities
Act, on the day of the happening of any event as a result of which the prospectus included in the Registration Statement contains an untrue statement of a material fact or omits any fact necessary to make the statements in the prospectus not
misleading; and prepare a supplement or amendment to the prospectus so that, when delivered to purchasers of the Shares or the Warrant Shares, the 
  

 18 

 prospectus, as supplemented or amended, does not contain an untrue statement of a material fact or omit to state any fact
necessary to make the statements in the prospectus not misleading, and notify the Purchaser on the day of the filing of such supplement or amendment; 
  
 (j) cause all such Shares and Warrant Shares to be quoted on the Nasdaq National Market and listed on any other exchange on which the Company’s
shares of common stock are listed; 
  
 (k) upon execution of a
nondisclosure agreement, in form reasonably satisfactory to the Company, by each person to whom information will be disclosed, make available for inspection by each Purchaser, any underwriter participating in any disposition pursuant to the
Registration Statement and any attorney, accountant or other agent retained by any Purchaser or any such underwriter, all financial and other records, pertinent corporate documents and properties of the Company, and cause the Company’s
officers, employees and independent accountants to supply all information reasonably requested by any Purchaser or any such underwriter, attorney, accountant or agent in connection with the Registration Statement; 
  
 (l) in the event of the issuance of any stop order suspending the
effectiveness of the Registration Statement, or of any order suspending or preventing the use of any related prospectus or suspending the qualification of any securities included in the Registration Statement for sale in any jurisdiction, notify
each Purchaser on the day of such issuance, use its commercially reasonable best efforts promptly to obtain the withdrawal of such order, and notify each Purchaser on the day of such withdrawal; 
  
 (m) file a Form D with respect to the Securities as required under
Regulation D and provide a copy thereof to the Purchaser promptly upon request by the Purchaser; 
  
 (n) issue a press release describing the transactions contemplated by this Agreement on the Closing Date; 
  
 (o) bear all expenses in connection with the Company’s performance of
or compliance with paragraphs (a) through (n) of this SECTION 7.1 and the Company’s registration of the Shares pursuant to the Registration Statement (other than fees and expenses, if any, of legal counsel (subject to Section 19
hereof) or other advisers to the Purchasers or underwriting discounts, brokerage fees and commissions incurred by the Purchasers, if any). 
  
 The Company understands that the Purchaser disclaims being an underwriter, but the Purchaser being deemed an underwriter shall not relieve the Company of
any obligations it has hereunder. Notwithstanding the foregoing, the parties understand and agree that the Company shall not be obligated to retain an underwriter with respect to the offer and sale of Shares and Warrant Shares pursuant to the
Registration Statement. 
  
 7.2 Transfer of Securities After
Registration. The Purchaser agrees that it will not effect any disposition of the Securities or its right to purchase the Securities that would constitute a sale within the meaning of the Securities Act or any applicable state securities laws,
except as contemplated in the Registration Statement referred to in SECTION 7.1 or as otherwise permitted by law. 
  

 19 

 7.3 Indemnification. 
  
 (a) The Company will indemnify and hold harmless each Purchaser and its officers, directors, members, employees and agents,
successors and assigns, and each other person, if any, who controls such Purchaser within the meaning of the Securities Act, against any losses, claims, damages or liabilities, joint or several, to which they may become subject under the Securities
Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon: (i) any untrue statement or alleged untrue statement of any material fact contained in any Registration
Statement, any preliminary prospectus or final prospectus contained therein, or any amendment or supplement thereof; (ii) any blue sky application or other document executed by the Company specifically for that purpose or based upon written
information furnished by the Company filed in any state or other jurisdiction in order to qualify any or all of the Shares and Warrant Shares under the securities laws thereof (any such application, document or information herein called a “Blue
Sky Application”); (iii) the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; (iv) any violation by the Company or its agents of
any rule or regulation promulgated under the Securities Act applicable to the Company or its agents and relating to action or inaction required of the Company in connection with such registration; (v) any failure to register or qualify the
Shares and Warrant Shares included in any such registration in any state where the Company or its agents has affirmatively undertaken or agreed in writing that the Company will undertake such registration or qualification on a Purchaser’s
behalf, and (vi) any breach or violation by the Company of the terms hereof and will reimburse such Purchaser and each officer, director, member, employee, agent, successor, assign and each such controlling person for any out-of-pocket legal
and other expenses reasonably incurred by them in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the Company will not be liable in any such case if and to the extent that any
such loss, claim, damage or liability arises out of or is based upon (A) an untrue statement or alleged untrue statement or omission or alleged omission so made in conformity with information furnished by or on behalf of such Purchaser or any
such controlling person in writing specifically for use in such Registration Statement or Prospectus or any amendments to or supplement thereof or (B) the failure of such Purchaser to comply with the covenants and agreements contained in this
Agreement respecting resale of the Securities. 
  
 (b) The
Purchaser agrees, severally but not jointly, to indemnify and hold harmless, to the fullest extent permitted by law, the Company, its directors, officers, employees, stockholders and each person who controls the Company (within the meaning of the
Securities Act) against any losses, claims, damages, liabilities and expense (including reasonable attorney fees) resulting from (i) any failure of such Purchaser to comply with the covenants and agreements contained in this Agreement
respecting resale of the Securities or (ii) any untrue statement of a material fact or any omission of a material fact required to be stated in the Registration Statement or Prospectus or preliminary prospectus or amendment or supplement
thereto or necessary to make the statements therein not misleading, to the extent, but only to the extent that such untrue statement or omission is contained in any information furnished in writing by or on behalf of such Purchaser to the Company
specifically for inclusion in such Registration Statement or Prospectus or amendment or supplement thereto, and such Purchaser will reimburse the Company, each of its directors, officers, agents and employees, and any 
  

 20 

 controlling persons for any out-of-pocket legal and other expenses reasonably incurred by the Company, its directors,
officers, agents or employees, or any controlling persons in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. In no event shall the liability of a Purchaser be
greater in amount than the dollar amount of the proceeds (net of all expense paid by such Purchaser in connection with any claim relating to this Section 7 and the amount of any damages such Purchaser has otherwise been required to pay by
reason of such untrue statement or omission) received by such Purchaser upon the sale of the Shares and/or Warrant Shares included in the Registration Statement giving rise to such indemnification obligation. 
  
 (c) Any person entitled to indemnification hereunder shall (i) give
prompt notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party;
provided that any person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such person unless
(a) the indemnifying party has agreed to pay such fees or expenses, or (b) the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c) in the reasonable
judgment of any such person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying party with respect to such claims (in which case, if the person notifies the indemnifying party in writing
that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on behalf of such person); and provided, further, that the failure of
any indemnified party to give notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the
defense of any such claim or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for
all such indemnified parties (including indemnified parties under Agreements with Other Purchasers). No indemnifying party will, except with the consent of the indemnified party, consent to entry of any judgment or enter into any settlement that
does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such claim or litigation. In no event shall any indemnifying party be liable in respect
of any amounts paid in settlement of any action unless the indemnifying party shall have approved in writing the terms of such settlement; provided that such consent shall not be unreasonably withheld. 
  
 (d) If the indemnification provided for in this SECTION 7.3 is required by
its terms but is for any reason held to be unavailable to or otherwise insufficient to hold harmless an indemnified party under paragraphs (a), (b) or (c) of this SECTION 7.3 in respect to any losses, claims, damages, liabilities or
expenses referred to herein, then each applicable indemnifying party shall contribute to the amount paid or payable by such indemnified party as a result of any losses, claims, damages, liabilities or expenses referred to herein (i) in such
proportion as is appropriate to reflect the relative benefits received by the Company and the Purchaser from the private placement of Securities hereunder or (ii) if the allocation provided by clause (i) above is not permitted by
applicable law, in such proportion as 
  

 21 

 is appropriate to reflect not only the relative benefits referred to in clause (i) above but the relative fault of
the Company and the Purchaser in connection with the statements or omissions or inaccuracies in the representations and warranties in this Agreement and/or the Registration Statement which resulted in such losses, claims, damages, liabilities or
expenses, as well as any other relevant equitable considerations. The respective relative benefits received by the Company on the one hand and the Purchaser on the other shall be deemed to be in the same proportion as the amount paid by the
Purchaser to the Company pursuant to this Agreement for the Shares purchased by the Purchaser that were sold pursuant to the Registration Statement bears to the difference (the “Difference”) between the amount the Purchaser paid for the
Shares that were sold pursuant to the Registration Statement and the amount received by the Purchaser from such sale. The relative fault of the Company, on the one hand, and the Purchaser on the other shall be determined by reference to, among other
things, whether the untrue or alleged statement of a material fact or the omission or alleged omission to state a material fact or the inaccurate or the alleged inaccurate representation and/or warranty relates to information supplied by the Company
or by the Purchaser and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The amount paid or payable by a party as a result of the losses, claims, damages,
liabilities and expenses referred to above shall be deemed to include, subject to the limitations set forth in paragraph (c) of this SECTION 7.3, any legal or other fees or expenses reasonably incurred by such party in connection with
investigating or defending any action or claim. The provisions set forth in paragraph (c) of this SECTION 7.3 with respect to the notice of the threat or commencement of any threat or action shall apply if a claim for contribution is to be made
under this paragraph (d); provided, however, that no additional notice shall be required with respect to any threat or action for which notice has been given under paragraph (c) for purposes of indemnification. The Company and the
Purchaser agree that it would not be just and equitable if contribution pursuant to this SECTION 7.3 were determined solely by pro rata allocation (even if the Purchaser were treated as one entity for such purpose) or by any other method of
allocation which does not take account of the equitable considerations referred to in this paragraph. Notwithstanding the provisions of this SECTION 7.3, the Purchaser shall not be required to contribute any amount in excess of the amount by which
the Difference exceeds the amount of any damages that the Purchaser has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the
meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Purchaser’s obligation to contribute pursuant to this SECTION 7.3 is several and
not joint. 
  
 7.4 Termination of Conditions and
Obligations. The restrictions imposed by SECTION 5 or this SECTION 7 upon the transferability of the Shares and Warrant Shares shall cease and terminate as to any particular number of the Shares or the Warrant Shares upon the earliest to occur
of (i) the sale of the Shares or the Warrant Shares pursuant to the Registration Statement, (ii) the sale of the Shares or the Warrant Shares pursuant to Rule 144 under the Securities Act, or (iii) the passage of two years from the
effective date of the Registration Statement covering such Shares or Warrant Shares or at such time as an opinion of counsel satisfactory in form and substance to the Company shall have been rendered to the effect that such conditions are not
necessary in order to comply with the Securities Act. 
  

 22 

 SECTION 8. Broker’s Fee. The Purchaser acknowledges that the Company intends to pay to the
Placement Agent a fee in respect of the sale of the Securities to the Purchaser. The Purchaser and the Company hereby agree that the Purchaser shall not be responsible for such fee and that the Company will indemnify and hold harmless the Purchaser
and each Purchaser/Affiliate against any losses, claims, damages, liabilities or expenses, joint or several, to which such Purchaser or Purchaser/Affiliate may become subject with respect to such fee. Each of the parties hereto hereby represents
that, on the basis of any actions and agreements by it, there are no other brokers or finders entitled to compensation in connection with the sale of the Securities to the Purchaser. 
  
 SECTION 9. Notices. All notices, requests, consents and other communications hereunder shall be in writing and shall
be deemed effectively given: (a) upon delivery to the party to be notified; (b) when received by confirmed facsimile or (c) one (1) business day after deposit with a nationally recognized overnight courier, specifying next business day delivery,
with written verification of receipt. All notices, requests, consents and other communications shall be sent to the Company and the Purchaser as follows or at such other addresses as the Company or the Purchaser may designate upon written notice to
the other party: 
  
 (a) if to the Company, to: 
  
 MetaSolv, Inc. 
 5556 Tennyson Parkway 
 Plano, TX 75024

 Attn: Chief Financial Officer 
 Facsimile: (972) 403-8989 
  
 with a copy to:

  
 MetaSolv, Inc. 
 5556 Tennyson Parkway 
 Plano, TX 75024

 Attn: Jonathan K. Hustis 
 Facsimile: (972) 403-8989 
  
 with a copy to:

  
 Vinson & Elkins L.L.P. 
 3700 Trammell Crow Center 
 2001 Ross Avenue

 Dallas, TX 75201-2975 
 Attention: Jeffrey A. Chapman 
 Facsimile: (214) 220-7716 
  
 (b) if to the Purchaser, at its address as set forth on the signature pages of this Agreement. 
  

 23 

 SECTION 10. Changes. This Agreement may not be modified or amended except pursuant to an
instrument in writing signed by the Company and the Purchaser. No provision hereunder may be waived other than in a written instrument executed by the waiving party. 
  
 SECTION 11. Headings. The headings of the various sections of this Agreement have been inserted for convenience of
reference only and shall not be deemed to be part of this Agreement. 
  
 SECTION 12. Severability. In case any provision contained in this Agreement should be invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not
in any way be affected or impaired thereby. 
  
 SECTION 13.
Governing Law; Jurisdiction; Service of Process. This Agreement shall be governed by and construed in accordance with the laws of the State of New York and the federal law of the United States of America. Any action or proceeding seeking to
enforce any provision of, or based on any right arising out of, this Agreement shall be brought against any of the parties in the courts of the State of New York, County of New York, or, if it has or can acquire jurisdiction, in the United States
District Court of the Southern District of New York, and each of the parties consents to the jurisdiction of such courts (and of the appropriate appellate courts) in any such action or proceeding and waives any objection to venue laid therein.
Process in any action or proceeding referred to in the preceding sentence may be served on any party anywhere in the world. 
  
 SECTION 14. Counterparts. This Agreement may be executed in two or more counterparts, each of which shall constitute an original, but all of
which, when taken together, shall constitute but one instrument, and shall become effective when one or more counterparts have been signed by each party hereto and delivered (including by facsimile) to the other parties. 
  
 SECTION 15. Entire Agreement. This Agreement and the instruments
referenced herein contain the entire understanding of the parties with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor the Purchaser makes any representation,
warranty, covenant or undertaking with respect to such matters. This Agreement supersedes all prior agreements and understandings among the parties hereto with respect to the subject matter hereof. 
  
 SECTION 16. Assignment. Except as otherwise expressly provided
herein, the provisions hereof shall inure to the benefit of, and be binding upon, the parties hereto and their respective permitted successors, assigns, heirs, executors and administrators. This Agreement and the rights of the Purchaser hereunder
may be assigned by Purchaser, provided that such assignee is an accredited investor (within the meaning of Regulation D under the Securities Act) and agrees in writing to be bound by the terms of this Agreement. 
  
 SECTION 17. Further Assurances. Each party agrees to cooperate fully
with the other parties and to execute such further instruments, documents and agreements and to 
  

 24 

 give such further written assurance as may be reasonably requested by any other party to evidence and reflect the
transactions described herein and contemplated hereby and to carry into effect the intents and purposes of this Agreement. 
  
 SECTION 18. Publicity. Except as set forth below, no public release or announcement concerning the transactions contemplated hereby shall be
issued by the Company or the Purchaser without the prior consent of the Company (in the case of a release or announcement by the Purchaser) or Lowenstein Sandler PC (on behalf of the Purchasers) (in the case of a release or announcement by the
Company) (which consents shall not be unreasonably withheld), except as such release or announcement may be required by law or the applicable rules or regulations of any securities exchange or securities market, in which case the Company or the
Purchaser, as the case may be, shall allow the Lowenstein Sandler PC (on behalf of the Purchasers) or the Company, as applicable, to the extent reasonably practicable in the circumstances, reasonable time to comment on such release or announcement
in advance of such issuance. By 8:30 a.m. (New York City time) on the trading day immediately following the Closing Date, the Company shall issue a press release disclosing the consummation of the transactions contemplated by the Transaction
Documents. No later than the third trading day following the Closing Date, the Company will file a Current Report on Form 8-K attaching the press release described in the foregoing sentence as well as copies of the forms of the Transaction
Documents. In addition, the Company will make such other filings and notices in the manner and time required by the Commission or Nasdaq. The Purchaser shall not issue any press release or make any other public statements with respect to the
Offering without receiving the prior written approval of the Company. 
  
 SECTION 19. Expenses. The parties hereto shall pay their own costs and expenses in connection herewith, except that the Company shall pay the reasonable fees and expenses of Lowenstein Sandler PC not to exceed $30,000 and the
reasonable fees and expenses of Ropes & Gray LLP not to exceed $5,000. Such expenses shall be paid not later than the Closing. The Company shall reimburse the Purchaser upon demand for all reasonable out-of-pocket expenses incurred by the
Purchaser, including without limitation reimbursement of attorneys’ fees and disbursements, in connection with any amendment, modification or waiver of this Agreement or the other Transaction Documents that is requested by the Company.

  
 [Remainder of page is intentionally blank] 
  

 25 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed by their duly authorized
representatives as of the day and year first above written. 
  

					
	 	 	METASOLV, INC.
			
	 	 	By	 	  

	 	 	Name:	 	  

	 	 	Title:	 	  

	Print or Type:            	 	 	 	 
	 	 	Name of Purchaser
	 	 	 (Individual or Institution):
  
  

  

	 	 	Name of Individual representing Purchaser
	 	 	 (if an Institution):
  
  

  

	 	 	Title of Individual representing
	 	 	 Purchaser (if an Institution):
  
  

  

	Signature by:            	 	 	 	 
		
	 	 	Individual Purchaser or Individual
	 	 	 representing Purchaser:
  
  

  

	 	 	Address:	 	  

  

  

			
	 	 	Telephone:	 	  

			
	 	 	Telecopier:	 	  

  
 [SIGNATURE PAGE TO
PURCHASE AGREEMENT] 

 SUMMARY INSTRUCTION SHEET FOR PURCHASER 
  
 (to be read in conjunction with the entire 
 Purchase Agreement that follows) 
  

	A.	Complete the following items on BOTH Purchase Agreements (Please sign two originals) 

  

	 	1.	Signature Page: 

  

	 	(i)	Name of Purchaser (Individual or Institution) 

  

	 	(ii)	Name of Individual representing Purchaser (if an Institution) 

  

	 	(iii)	Title of Individual representing Purchaser (if an Institution) 

  

	 	(iv)	Signature of Individual Purchaser or Individual representing Purchaser 

  

	 	2.	Appendix I - Securities Certificate Questionnaire: 

  
 Provide the information requested by the Securities Certificate Questionnaire. 
  

	 	3.	Appendix II - Registration Statement Questionnaire: 

  
 Provide the information requested by the Registration Statement Questionnaire. 
  

	 	4.	Return BOTH properly completed and signed Purchase Agreements including the properly completed Appendix I and Appendix II to (initially by facsimile with hard copy by
overnight delivery): 

  
 Vinson & Elkins
L.L.P. 
 Trammell Crow Center 
 2001 Ross Avenue, Suite 3700 
 Dallas, Texas 75201-2975 
 Attention: Victoria Mitchell 
 Facsimile: (214) 999-7827 
  

	B.	Upon the resale of the Shares by the Purchaser after the Registration Statement covering the Shares is effective, as described in the Purchase Agreement, the Purchaser:

  

	 	1.	must deliver a current prospectus of the Company to the buyer (prospectuses may be obtained from the Company at the Purchaser’s request) if the Company has notified the
Purchaser that the conditions specified in Rule 172(c)(1) or Rule 172(c)(2) under the Securities Act are not satisfied; and 

  

	 	2.	must send a letter in the form of Appendix III to the Company so that the Shares may be properly transferred. 

 APPENDIX I 
  
 METASOLV, INC. 
 SECURITIES
CERTIFICATE QUESTIONNAIRE 
  
 Pursuant to SECTION 3 of the
Agreement, please provide us with the following information: 
  

					
	 1.
	  	The exact name that your Securities are to be registered in (this is the name that will appear on your stock certificate(s) and Warrant Certificate(s)). You may use a nominee name if
appropriate:	  	                                      
          
			
	 2.
	  	The relationship between the Purchaser of the Securities and the Registered Holder listed in response to item 1 above:	  	                                      
          
			
	 3.
	  	The mailing address of the Registered Holder listed in response to item 1 above:	  	                                       
          
                                       
          
                                       
          
                                       
          

			
	 4.
	  	The Social Security Number or Tax Identification Number of the Registered Holder listed in response to item 1 above:	  	                                      
          

 APPENDIX II 
 (Page 1 of 2) 
  
 METASOLV, INC.

 REGISTRATION STATEMENT QUESTIONNAIRE 
  
 In connection with the preparation of the Registration Statement, please provide us with the information set forth below. You agree that the Company may
present this Questionnaire to such parties as it deems appropriate to establish the availability of exemptions from registration under state and federal securities laws. 
  
 SECTION 1. Pursuant to the “Selling Stockholder” section of the Registration Statement, please state your or your
organization’s name exactly as it should appear in the Registration Statement: 
  
                                       
                                        
                                        
                                        
           
  
 SECTION 2. Please provide the number of shares that you or your organization will beneficially own immediately after Closing, including those Securities purchased by you or your organization pursuant to the Purchase Agreement and those
shares purchased by you or your organization through other transactions: 
  
                                       
                                        
                                        
                                        
           
  
 SECTION 3. Have you or your organization had any position, office or other material relationship within the past three years with the Company or its affiliates? 
  
  ̈    Yes     ̈    No 
  
 If “yes,” please indicate the nature of any such relationships
below: 
  
                                       
                                        
                                        
                                        
                           
  

                                      
                                        
                                        
                                        
                           
  

                                      
                                        
                                        
                                        
                           
  

SECTION 4. Are you (b) an NASD Member (see definition), (c) a Controlling (see definition) shareholder of an NASD Member, (d) a Person
Associated with a Member of the NASD (see definition), or (e) an Underwriter or a Related Person (see definition) with respect to the proposed offering; or (b) do you own any shares or other securities of any NASD Member not purchased in
the open market; or (c) have you made any outstanding subordinated loans to any NASD Member? 
  
 Answer:  ̈    Yes     ̈    No 
  

 29 

 APPENDIX II 
 (Page 2 of 2) 
  
 If
“yes,” please describe below: 
  
                                       
                                        
                                        
                                        
                   
  
                                       
                                        
                                        
                                        
                   
  
                                       
                                        
                                        
                                        
                   
  
 NASD Member. The term “NASD member” means either any broker or dealer admitted to membership in the National Association of Securities
Dealers, Inc. (“NASD”). (NASD Manual, By-laws Article I, Definitions) 
  
 Control. The term “control” (including the terms “controlling,” “controlled by” and “under common control with”) means the possession, direct or indirect, of the power,
either individually or with others, to direct or cause the direction of the management and policies of a person, whether through the ownership of voting securities, by contract, or otherwise. (Rule 405 under the Securities Act of 1933, as amended)

  
 Person Associated with a Member of the NASD. The term
“person associated with a member of the NASD” means every sole proprietor, partner, officer, director, branch manager or executive representative of any NASD Member, or any natural person occupying a similar status or performing similar
functions, or any natural person engaged in the investment banking or securities business who is directly or indirectly controlling or controlled by a NASD Member, whether or not such person is registered or exempt from registration with the NASD
pursuant to its bylaws. (NASD Manual, By-laws Article I, Definitions) 
  
 Underwriter or a Related Person. The term “underwriter or a related person” means, with respect to a proposed offering, underwriters, underwriters’ counsel, financial consultants and advisors, finders, members of the
selling or distribution group, and any and all other persons associated with or related to any of such persons. (NASD Interpretation) 

 APPENDIX III 
  
 [Transfer Agent] 
 [Address] 
  
 Attention: 
  
 PURCHASER’S CERTIFICATE OF SUBSEQUENT SALE 
  
 The undersigned, [an officer of, or other person duly authorized by]

                                       
                                        
                                        
                                        
               hereby certifies 
                                        
 [fill in official name of individual or institution] 
  
 that [he/she/said
institution] is the Purchaser of the shares evidenced by the attached certificate, and as such, sold 
                                       
               of such shares on
                             in accordance with the terms of the Purchase Agreement 

	        [fill	in number of
shares]                                        
[date] 

  
 and in accordance with Registration Statement number
                                        
                                        
                                        
     
                                        
                                        
                 [fill in the number of or otherwise identify Registration Statement] 
  
 or otherwise in accordance with the Securities Act of 1933, as amended, and, in the case of a transfer pursuant to the Registration
Statement, at a time when the Company has notified the Purchaser that the conditions specified in Rule 172(c)(1) or Rule 172(c)(2) under the Securities Act are not satisfied, the requirement of delivering a current prospectus by the Company has been
complied with in connection with such sale. 
  
 Print or Type: 
  
 Name of Purchaser 
 (Individual 
 or Institution):
                                        
     
  
 Name of Individual 
 representing 
 Purchaser (if an 
 Institution)
                                        
           
  
 Title of Individual 
 representing 
 Purchaser 
 (if an Institution):
                                       

  
 Signature by: 
  
 Individual Purchaser 
 or Individual 
 representing 
 Purchaser:
                                        
            

 APPENDIX IV 
  
 Plan of Distribution 
  
 The selling stockholders, which as used herein includes donees, pledgees, transferees or other successors-in-interest selling shares of common stock or
interests in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of
their shares of common stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices
at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. 
  
 The selling stockholders may use any one or more of the following methods when disposing of shares or interests therein: 
  
 - ordinary brokerage transactions and transactions in which the
broker-dealer solicits purchasers; 
  
 - block trades in which the
broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction; 
  
 - purchases by a broker-dealer as principal and resale by the broker-dealer for its account; 
  
 - an exchange distribution in accordance with the rules of the applicable exchange; 
  
 - privately negotiated transactions; 
  
 - short sales effected after the date the registration statement of which
this Prospectus is a part is declared effective by the SEC; 
  
 -
through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; 
  
 - broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share; and 
  
 - a combination of any such methods of sale. 
  
 The selling stockholders may, from time to time, pledge or grant a security
interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this
prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as 

 

 32 

 selling stockholders under this prospectus. The selling stockholders also may transfer the shares of common stock in
other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus. 
  
 In connection with the sale of our common stock or interests therein, the selling stockholders may enter into hedging
transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of our common stock short
and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions with
broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer
or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). 
  
 The aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less
discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through
agents. We will not receive any of the proceeds from this offering. Upon any exercise of the warrants by payment of cash, however, we will receive the exercise price of the warrants. 
  
 The selling stockholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule
144 under the Securities Act of 1933, provided that they meet the criteria and conform to the requirements of that rule. 
  
 The selling stockholders and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be
“underwriters” within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities Act.
Selling stockholders who are “underwriters” within the meaning of Section 2(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act. 
  
 To the extent required, the shares of our common stock to be sold, the names
of the selling stockholders, the respective purchase prices and public offering prices, the names of any agents, dealer or underwriter, any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying
prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus. 
  
 In order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered or
licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with.

  

 33 

 We have advised the selling stockholders that the anti-manipulation rules of Regulation M under the
Exchange Act may apply to sales of shares in the market and to the activities of the selling stockholders and their affiliates. In addition, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to
the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against
certain liabilities, including liabilities arising under the Securities Act. 
  
 We have agreed to indemnify the selling stockholders against liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the shares offered by this
prospectus. 
  
 We have agreed with the selling stockholders to
keep the registration statement of which this prospectus constitutes a part effective until the earlier of (1) such time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with the registration
statement or (2) the date on which the shares may be sold pursuant to Rule 144(k) of the Securities Act. 
  

 34 

 EXHIBIT A 
  
 [Form Of Warrant Certificate] 

 EXHIBIT B 
  

			
	 Name of Subsidiary

	  	 Jurisdiction of Formation

	 MetaSolv Software, Inc.
	  	 Delaware

	 MetaSolv Canada Inc.
	  	 Canada

	 MetaSolv Canada Holdings Inc.
	  	 Canada

	 MetaSolv Software Canada Inc.
	  	 Canada

	 MetaSolv Software (UK) Limited
	  	 United Kingdom

 EXHIBIT C 
  
 Opinion Of Counsel To The Company 
  
 The opinion will be subject to standard qualifications and exceptions, the standard form of Vinson & Elkins L.L.P., legal counsel to the Company,
and review and approval of the Vinson & Elkins L.L.P. opinion committee. 
  

	 	1.	The Company is a corporation validly existing and in good standing under the laws of the State of Delaware with corporate power to enter into and perform its obligations under the
Transaction Documents. The Company is duly qualified to do business and is in good standing as a foreign corporation in the State of Texas. 

  

	 	2.	MetaSolv Software, Inc. is validly existing and is in good standing under the laws of the State of Delaware. 

  

	 	3.	The authorized capital stock of the Company as of October     , 2005, is as set forth in Section 4.2 of the Company Disclosure
Schedules. 

  

	 	4.	The Shares have been duly authorized and, when issued and paid for in accordance with the Agreement, will be validly issued, fully paid and nonassessable. Upon the due exercise of
the Warrants, the Warrant Shares issuable upon such exercise will be validly issued, fully paid and non-assessable. The Company has reserved a sufficient number of shares of Common Stock for issuance upon the exercise of the Warrants.

  

	 	5.	The Company has the corporate power and authority and has taken all requisite corporate action necessary to (i) execute and deliver the Transaction Documents, (ii) perform
all obligations of the Company under the Transaction Documents, and (iii) issue (or reserve for issuance) and deliver the Securities. The execution and delivery by the Company of the Transaction Documents, the issuance and sale of the
Securities and the consummation by the Company of the other transactions contemplated by the Transaction Documents, have been duly authorized by all necessary corporate action on the part of the Company, and each Transaction Document has been duly
executed and delivered by the Company. 

  

	 	6.	To our knowledge, no Person is entitled to any preemptive right or right of first refusal with respect to the issuance of the Securities. 

  

	 	7.	The execution, delivery and performance by the Company of the Transaction Documents and the offer, issuance and sale of the Securities do not conflict with or result in a breach or
violation of (a) the Company’s Certificate of Incorporation or By-laws, each as amended to date, (b) the current Delaware General Corporation Law or any federal or State of Texas statute, rule or regulation that we have, in the
exercise of customary professional diligence, recognized as applicable to the Company or the transactions contemplated by the Transaction Documents, except that, except as set forth in paragraph 10 below, we express no opinion regarding Federal,
Blue Sky or state securities laws, (c) any order, writ, judgment or decree known to us to which the Company or any of its Subsidiaries 

 is subject or (d) any contract that is filed with or incorporated by reference in the Company’s
Annual Report on Form 10-K for the fiscal year ended December 31, 2004, and the Exchange Act Filings filed with the Commission after such Annual Report on Form 10-K through the date hereof and any other contract disclosed to us by the Company
as being material to the Company and listed on an exhibit to the opinion (a “Company Contract”). 
  

	 	8.	The execution, delivery and performance by the Company of the Transaction Documents and the offer, issuance and sale of the Securities do not and will not, require any consent of,
action by, or filing with any governmental authority known to us or any other Person under any Company Contract, except that, except as set forth in paragraph 10 below, we express no opinion regarding Federal, Blue Sky or state securities laws.

  

	 	9.	To our knowledge, except as described in Section 4.8 of the Company Disclosure Schedule, there are no material legal or governmental proceedings pending to which the
Company or its Subsidiaries is a party or of which any property of the Company or its Subsidiaries is the subject. 

  

	 	10.	Assuming the Investment Representations made by the Purchasers in the Transaction Documents are true and correct, the initial sale of the Securities as contemplated by the
Transaction Documents is exempt from the registration and prospectus delivery requirements of the Securities Act of 1933.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00092-of-00352.parquet"}]]